Barcoded nanocarrier-based arrays for profiling biological targets

The multivalent display library using nanocarriers with non-covalently attached ligands and silent barcodes simplifies the screening of synergistic protein-ligand interactions, enhancing the efficiency and accuracy of identifying synergistic binding.

WO2026236850A1PCT designated stage Publication Date: 2026-11-19THE GOVERNORS OF THE UNIV OF ALBERTA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CA2026/050702
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-08-19
Filing Date
2026-05-15
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing methods for screening synergistic interactions between multiple ligands and receptors are complex and inefficient, particularly in identifying synergistic protein-ligand interactions, as they require exponentially more tests and often compromise library complexity.

Method used

A multivalent display library using nanocarriers with non-covalently attached ligands and silent barcodes that encode ligand identity or properties, allowing for simultaneous screening of multiple ligands in a mixed solution.

Benefits of technology

Enables efficient identification of synergistic interactions by reducing the complexity of screening processes and providing a feasible method for characterizing targets with high-throughput and accuracy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CA2026050702_19112026_PF_FP_ABST
    Figure CA2026050702_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates generally to barcoded nanocarrier-based arrays, which can be used for multiplexed biomolecule display, screening, and profiling of biological targets. In some examples, the arrays are used for cell-surface profiling. In at least one example, the nanocarrier-based arrays include phage-based carriers using streptavidin-biotin coupling. In some examples, there is provided a multivalent display library, comprising at least one nanocarrier population comprising nanocarriers associated with at least one distinct barcode, wherein the nanocarriers bear a surface universal adapter and a ligand associated with the universal adapter, wherein the barcode uniquely encodes the identity of the ligand and / or a ligand property such as ligand density, and wherein the universal adapter is non- covalently attached to the ligand.
Need to check novelty before this filing date? Find Prior Art

Description

BARCODED NANOCARRIER-BASED ARRAYS FOR PROFILING BIOLOGICALTARGETSCROSS-REFERENCE TO RELATED

[0001] The present application claims priority to, and the benefit of, United States Provisional Patent Application No. 63 / 807,077, filed on May 16, 2025, and United States Provisional Patent Application No. 63 / 866,726, filed on August 19, 2025, the contents of each of which are incorporated herein by reference in their entirety.LISTING

[0002] The present application is being filed along with a Sequence Listing in ST.26 XML format. The Sequence Listing is provided as a file titled “SEQ Barcoded Nanocarrier-Based Array .xml” created May 15, 2026, and is 34.2 kilobytes in size. The Sequence Listing information in the ST.26 XML format is incorporated herein by reference in its entirety.FIELD

[0003] The present disclosure relates generally to barcoded nanocarrier-based arrays, which can be used for multiplexed biomolecule display, screening, and profiling of biological targets. In some examples, the arrays are used for cell-surface profiling. In at least one example, the nanocarrierbased arrays include phage-based carriers using streptavidin-biotin coupling.BACKGROUND

[0004] It is known that many proteins and other macromolecular receptors can interact with more than one ligand. Simultaneous interaction of the receptor with two ligands often produces different biophysical, biochemical and physiological outcomes than the interaction of the same receptor with either of the ligands individually. Such interactions, when the binding of two molecules proves to be more advantageous than the binding of either ligand individually, are termed "synergistic" or "positively cooperative" . These "synergistic" interactions may be of interest in fields that deal with receptor-ligand interactions (e.g., drug discovery, diagnostics, and basic research).- 1 -WSLEGAL\055326\00571\44189453v4

[0005] One specific example of synergistic interaction is that of carbohydrates and proteins. Examples are known where two distinct types of glycans bind to one protein with significantly higher affinity than either one of the glycans alone. Among possible factors, the biophysical origin of such an enhancement may be due to allosteric conformational change within the protein structure, or interactions of two molecules. Another example of synergistic interaction is that of B-cell receptors and multivalent presentation of antigens on nanoparticles. Multivalency improves immunogenicity by improving engagement of B-cell receptors which leads to increased antigen internalization, T-cell activation and antibody titres.

[0006] Many known methods in ligand discovery are optimized for discovery of individual ligands that bind to individual proteins, referred to here as "spatially-separated libraries" .

[0007] Examples include the screening of libraries of individual molecules on microtiter plates, the screening of molecular arrays, in which each molecule is attached to the surface in a specific location, or the screening of a one-bead-one-compound library where individual macroscopic (micronsized) beads bear a unique molecule. Upgrading "spatially-separated libraries" technology to permit for screening of synergistic interactions is theoretically possible but, in practice, it can be exponentially more complex. A library of N different molecules contains about Nd'l unique binary combinations. Therefore, for even a small library of 1,000 molecules, one needs to produce and test 500,000 binary combinations. This number scales to 200,000,000 for a trinary combination. Thus, to achieve a feasible result, it may be necessary to compromise the complexity of the library (i.e., make the number of tested library members smaller).

[0008] A well-known technology complementary to "spatially-separated libraries" is a "mixed library" technology, in which multiple molecules are present in the same solution. This technology allows screening of a mixture of molecules and is a "display" technology.

[0009] A mixed library technology is suited for identification of synergistic binding because all molecules are present in the same solution. Identification of synergistic interactions using mixed encoded libraries has been documented using glycan and lectin-displaying bacteriophages.

[0010] Notwithstanding the above, there exists a need to provide an effective method of identifying molecules for drug discovery, diagnostic development and basic research that studies protein-ligand interactions.- 2 -WSLEGAL\055326\00571\44189453v4

[0011] This background information is provided for the purpose of making known information believed by the applicant to be of possible relevance to the present invention. No admission is necessarily intended, nor should be construed, that any of the preceding information constitutes prior art against the present invention.SUMMARY

[0012] According to one broad aspect, there is disclosed a multivalent display library, comprising at least one nanocarrier population comprising nanocarriers associated with at least one distinct barcode, wherein the nanocarriers bear a surface universal adapter and a ligand associated with the universal adapter, wherein the barcode uniquely encodes the identity of the ligand and / or a ligand property such as ligand density, and wherein the universal adapter is non-covalently attached to the ligand.

[0013] In some embodiments, the at least one distinct barcode is a silent barcode.

[0014] In some embodiments, the library comprises two or more different nanocarrier populations, wherein each population comprises a different silent barcode, and each population differs in the identity of the ligand or a ligand property.

[0015] In some embodiments, the ligand property is a display density of the ligand on the nanocarrier.

[0016] In some embodiments, the barcode is prospectively associated with the nanocarriers, or is retrospectively associated with the nanocarriers.

[0017] In some embodiments, the universal adapter is streptavidin, avidin, neutravidin, a streptavidin-derived protein, dihydrofolate reductase, an antibody, or a protein that binds a small organic molecule or peptide with a dissociation constant of 10 nM or lower.

[0018] In some embodiments, the universal adapter is streptavidin and the ligand is biotinylated.

[0019] In some embodiments, the nanocarriers comprises cells, viruses such as phages such as bacteriophages, virus-like particles, liposomes, lipid nanoparticles, exosomes, vesicles, polymeric particles, nanoparticles, synthetic particles, or combinations thereof.- 3 -WSLEGAL\055326\00571\44189453v4

[0020] In some embodiments, the nanocarrier comprises a phage, such as bacteriophage, such as M13.

[0021] In some embodiments, the ligand is a gly can-binding protein, such as a lectin.

[0022] In another aspect, disclosed is a method of characterizing a target, comprising contacting the target with a library a described herein, and analyzing the binding of the at least one nanocarrier population to the target.

[0023] In some embodiments, the target is a heterogenous target, and the library is a mixed library described herein. The binding of the different nanocarrier populations to the heterogenous target is analyzed.

[0024] In some embodiments, the different nanocarrier populations each comprise a different lectin and / or a different display density of a lectin, and the heterogenous target is a glycocalyx.

[0025] In another aspect, disclosed is a method of preparing a multivalent display library comprising at least one nanocarrier population, comprising the steps of:(a) attaching a universal adapter to each nanocarrier and non-covalently associating a ligand with the universal adapter, such that the nanocarrier displays the ligand; and(b) associating at least one distinct barcode with the at least one nanocarrier population, such that the barcode uniquely identifies the ligand and / or a ligand property.

[0026] In some embodiments, the method further comprises the step of combining at least two different nanocarrier populations, wherein each population comprises a different silent barcode, and each population differs in the identity of the ligand or a ligand property.

[0027] In some embodiments, the at least one distinct barcode or silent barcode is prospectively or retrospectively associated with the nanocarriers.

[0028] Other features and advantages of the present application will become apparent from the following detailed description taken together with the accompanying drawings. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the application, are given by way of illustration only, since various changes and modifications within the spirit and scope of the application will become apparent to those skilled in the art from this detailed description.- 4 -WSLEGAL\055326\00571\44189453v4BRIEF DESCRIPTION OF THE DRAWINGS

[0029] For a better understanding of the various embodiments described herein, and to show more clearly how these various embodiments may be carried into effect, reference will be made, by way of example, to the accompanying drawings which show at least one example embodiment, and which are now described. The drawings are not intended to limit the scope of the teachings described herein.

[0030] FIG. 1 shows synthesis and quantification of streptavidin-displaying phages. (A) Scheme of cp-SA synthesis via chemical biotinylation of phage. (B) MALDI spectra of cp-biotin synthesis under various biotin concentrations. (C) Fluorescently-labeled streptavidin is used to quantify the amount of streptavidin copies per phage virion. Dividing phage fluorescence by the concentration of phage as measured by qPCR gives the total number of streptavidin copies as absolute values. (D) Calibration curve of SA-SA-Cy5 protein (E) Calibration curve of phages. In D-E, black dots represent standards, and purple dot represents values obtained for samples. Blue dot represents Cq of a sample containing no phages (blank sample) (F) Copy number of biotins and streptavidin per phage virions as measured by MALDI and fluorescence, respectively. Values represent mean of n = 5, All n values are independent biological replicates.

[0031] FIG. 2 shows optimization of cp-SA synthesis procedure for conjugation of biotinylated lectin. (A) Scheme of cp-lectin synthesis via non-covalent binding of biotinylated lectin to streptavidin-displaying phage. (B) Recovery of cp-CBM phages conjugated on SpyCatcher or SA-displaying phages from genetically engineered U937 cells measured by qPCR. Values represent mean of n = 3. All n values are independent technical replicates. (C) SDS-PAGE analysis of synthesis of cp-SA phages. (D) SDS-PAGE analysis of synthesis of cp- CBM phages. (E) Scheme of the procedure and observed outcomes for the removal of excess biotin-NHS-ester from the reaction mixture using dialysis and desalting column purification methods. (F) SDS-PAGE analysis of synthesis of cp-MBP phages.

[0032] FIG. 3 shows glycome profiling of genetically engineered U937 cells with phage clones and LiSA (A) Scheme of cell panning using individual phage clones. (B) Recovery of cp-SA-CBM, cp-SA-PNA, and cp-SA-MBP phages as measured by qPCR. For each cell binding experiment, a single phage construct was incubated with U937 cells followed by binding quantification by qPCR. (C) A defined set of five distinct DNA barcodes (or SDBs) is associated with a cp-SA phage which can - 5 -WSLEGAL\055326\00571\44189453v4be further functionalized with a lectin. Mixing of a pool of lectins can be used to probe the cell surface of cells. DNA barcodes are extracted from phage and amplified by PCR. Sequencing of DNA barcodes are decoded by NGS and used to quantify binding of a lectin to a cell. (D) Binding profile of Li SA on WT, CMASK0and ST3GAL1KOcells as measured by deep sequencing. FC of cp-SA-MBP clones was set to one. Values represent mean of n = 3 (technical replicates) x 5 (DNA barcodes per construct). Each color of the scatter plot represents one replicate.

[0033] FIG. 4 shows glycome profiling of genetically engineered U937 cells with LiLA, LiSA or LiLA+LiSA (A) Binding profile of LiLA on WT, CMASKOand CHST1 cells as measured by deep sequencing. LiLA is composed of cp-Sc-CBM, cp-Sc-Sig7, cp-Sc-Sig7R, cp-Sc-MBP, and cp-blank phages. (B) Binding profile of LiSA on WT, CMASK0and CHST1 cells as measured by deep sequencing. LiSA is composed of cp-SA-CBM, cp-SA-PNA, cp-SA-Lectenz, cp-SA-MBP, cp- SA-biotin and cp-blank. (C) Binding profile of LiLA+LiSA on WT, CMASKOand CHST1 cells as measured by deep sequencing. In A-C, FC of cp-blank clones was set to one. Values represent mean of n = 3 (technical replicates) x 5 (DNA barcodes per construct). Each color of the scatter plot represents one replicate.

[0034] FIG. 5 shows cp-SA aggregation qPCR plots. (A) Scheme of serial dilution series for quantifying the size of phage aggregates in the solution. Aggregates cannot be diluted to 1- 10 phage particles as opposed to non-aggregate phage solution. (B) qPCR plots of serial dilutions of cp-biotin (left), cp-SA prepared with 1 eq of SA (middle) and cp-SA prepared with 100-eq of SA (right) at a phage concentration of 5 x 1010PFU / ml. Grey dot indicates Cq value for blank solution (no phage added). (C) qPCR plots of cp-SA-lectin phages which have been purified by PEG / NaCl.

[0035] FIG.6 shows effect of concentration of phage, SA and biotinylated lectin on the size of phage aggregates. (A) Heatmap of relationship between phage / SA concentration and the size of aggregate as measured by qPCR. (B) MALDI spectra of MBP (top) and biotinylated MBP (bottom).(C) qPCR plots of serial dilutions of cp-MBP phages prepared with 3 equivalent molar concentration of biotinylated MBP. (D) qPCR plots of serial dilutions of cp-MBP phages prepared with 100 equivalent molar concentration of biotinylated MBP.

[0036] FIG. 7 shows effect of PEG / NaCl precipitation and SEC purification on binding of LiSA (A) qPCR plots of serial dilutions of cp-SA phages before (top) or after (bottom) PEG / NaCl precipitation. (B) Scheme of purification of phage particles from free floating proteins and small - 6 -WSLEGAL\055326\00571\44189453v4molecule by SEC. (C) SDS-PAGE of eluted fractions of sample containing blank phages and BSA. The pVIII phage band shows at ~9 kDa whereas band at ~66 kDA shows the BSA free protein. (D) Quantification of phage DNA from SEC eluted fractions as measured by qPCR. Dark blue bar shows total recovery of the 8 eluted fractions combined. (E) Distribution of phage constructs in LiSA samples before and after SEC purification (F) Phage recovery of LiSA from WT U937 cells, before or after SEC purification, as measured by qPCR (G) Binding profile of different LiSA preparations on WT U937 cells as measured by deep sequencing. FC of cp-SA- MBP clones was set to one. Values represent mean of n = 3 (technical replicates) x 5 (DNA barcodes per construct). Each color of the scatter plot represents one replicate.

[0037] FIG. 8 shows MALDI Spectra of biotinylated p8 protein, (a) MALDI spectra of cp-biotin synthesis at t = 0 (top) and t = 3 h (bottom) after desalting column. A 90% increase in the p8-biotin peak intensity has been noticed 3 h after using desalting column. Excess of biotin in the reaction mixture not only increases the number of biotinylated p8 proteins, but also interferes with binding of biotinylated lectins to streptavidin, as the streptavidin biotin-binding sites become occupied by free biotin present in the medium. MALDI spectra of cp-biotin synthesis at t = 0 (top) and t = 125 d (bottom) after dialysis. The number of biotinylated pVIII protein did not increase after 125 days.

[0038] FIG. 9 shows qPCR plots of SA aggregation analysis. Particularly, it shows the relationship between phage and SA concentration on the size of phage aggregate as measured by qPCR. SA amount ranged from 5 to 500 pmol and total amount of phage used in the reaction ranged from 5 x 109to 5 x 1011PFU. Grey dot indicates Cq value for blank solution (no phage added). Each color represents one concentration of SA. Cq analysis was used to plot heatmap in Figure 6A.

[0039] FIG. 10 shows influence of D-desthiobiotin on aggregate formation. (A) qPCR plots of serial dilutions of cp-biotin incubated with SA, SA pre- complexed with 10 pM biotin, and SA precomplexed with 1 mM desthiobiotin for Ih and overnight, (upper), cp-SA prepared with 1 eq of SA (middle). 10 eq of cp-SA was incubated with phage at a concentration of 5 x 1010PFU / ml. Grey dot indicates Cq value for blank solution (no phage added). (B) SDS-PAGE analysis of synthesis of cp-SA phages as a function of desthiobiotin concentration and incubation time. (C) In-gel fluorescence analysis of synthesis of cp-SA phages, cp-biotin phages were incubated with a solution of 9:1 SA-SA-Cy5.- 7 -WSLEGAL\055326\00571\44189453v4

[0040] FIG. 11 provides a scheme related to the construction of RNA-seq compatible capture sequence, a molecule barcode and unique molecular identifier (UMI) within a non- translatable region downstream the tetracycline gene (Ter), showing an example of how 1,048,576 (-106) possible barcode sequences could be generated for each molecule barcode: 410 = 1,048,576. The number of possible variations can be exponentially expanded by increasing the length of the barcode.

[0041] FIG. 12 provides an exemplary scheme of crosslinking proteins and other biomolecules to prospectively DNA barcoded barcoded phage and liposomes.

[0042] FIG. 13 provides an exemplary scheme of encoding and detecting proteins and other biomolecules presented on phage at different densities. Four prospectively DNA barcoded carriers that contain different prospectively DNA barcodes and UMIs can be modified with a mixture of proteins and / or other biomolecules at different densities, or a protein / biomolecule of different structure. Once the carriers are pooled together, selection and pull-down followed by deep sequencing can determine which protein / biomolecule and which density of protein / biomolecule exhibits the best interactions with the target by counting the number of total molecules in the sample (i.e. number of unique reads from UMI) for each associated molecule barcode.

[0043] FIG. 14 shows the recovery of proteins from library detected by deep-sequencing. The library shows the recovery of proteins from library detected by deep-sequencing and how they compare to binding as measured by flow cytometry. The library in the mixture contains a divalent form of the sialidase carbohydrate-binding module from Clostridium perfringens (diCBM40), catalytically inactive polySia specific lectin (EndoN), peanut agglutinin (PNA), Erythrina cristagalli lectin (ECL), StcE, Ulex europaeus agglutinin I (UEA), Concavalin A (ConA), and maltose-binding protein (MBP).

[0044] FIG. 15 shows the recovery of glycans from library detected by deep-sequencing. The library in the mixture contains a mixture of covalently attached glycans (C) and non-covalently attached glycans (B).

[0045] FIG. 16 shows (A) Schematic description of the genome of bacteriophage fd and locations for introduction of genetic parts. (B) UMI fd phages can be incubated with a mixture of genetically modified cells and (C) submitted for encapsulation and (D) binding to gel beads. (E) DNA from phage and mRNA from cells are released. (F) Capture sequence from genomic ssDNA released - 8 -WSLEGAL\055326\00571\44189453v4from phage can hybridize to single-cell gel beads. (G) Biological interactions can be decoded at singlecell and single-phage level after several PCR rounds. (H) Incorporation of randomized barcodes in the non-translatable region of the fd genome yields libraries with uniform distribution of nucleotides. (I) Number of unique reads in a phage library as quantified by deep sequencing. Each unique read (x-axis) represents a single phage particle.

[0046] FIG. 17 shows mixing isolated cells with LiLA ex vivo (top) vs. injection of the same LiLA in vivo (bottom). Certain lectins (e.g. PNA) that work in vitro show poor performance in vivo. Bone marrow cells cannot be accessed in vivo.

[0047] FIG. 18 shows preliminary results from in vivo panning of 50 peptide macrocycles in JMT-tumor bearing mice. (A) NGS analysis of fold change (FC) enrichment of peptides in tumor, spleen, liver and heart juxtaposed to EC50 values measured for these macrocycles in vitro using ELISA and flow cytometry; (B) peptides were displayed on prospectively-barcoded streptavidin-modified phage particles. (C) Negative controls were unmodified and phage chemically modified by PEG.

[0048] FIG. 19 shows construction of a DEMDOLON object (DNA Encoded Multivalent Display Of Ligands On a Nanoscale) by prospective barcoding wherein “prospective barcoding starts from introducing DNA inside the nanoscale object followed by covalent or non-covalent attachment of molecules to the surface of the object to create a multivalent display of molecules.

[0049] FIG. 20 shows production of DEMDOLON by retroactive barcoding wherein “retroactive barcoding starts from nanoscale objects that already contain a multivalent display of ligands on their surface and introduces a DNA barcode into or onto such object.

[0050] FIG. 21 shows use of DEMDOLON to select molecules that bind to the cells. The figure demonstrates the 1:1 correspondence between the structure of the glycan on the surface of LNP (Lipied NanoParticles) and DNA inside the LNP. DNA barcodes encode either LNP coated with CD33 -binding glycolipid or LNP with PEGylated glycolipid. The interactions of the LNPs with CD33 OE cells are decoded by qPCR. Flow cytometry data is shown as reference. (A) Representation of DNA-barcoded LNP -based DEMDOLON displaying active molecules (top) and inactive molecules (bottom). (B) Detection of binding of LNP -based DEMDOLON that binds to CD33 -overexpressing cell by flow cytometry. (C) Detection of binding of LNP -based DEMDOLON that binds to wild-type - 9 -WSLEGAL\055326\00571\44189453v4cell by flow cytometry. (D) Detection of binding of LNP -based DEMDOLON that binds to CD33-knock-out cells by flow cytometry. (E) Detection of binding of LNP-based DEMDOLON that binds to CD33 -overexpressing cell by qPCR. (F) Detection of binding of LNP-based DEMDOLON that binds to wild-type cell by qPCR. (G) Detection of binding of LNP-based DEMDOLON that binds to CD33 -knock-out cells by qPCR. (H) Chemical structure of active and inactive molecules.

[0051] FIG. 22 shows use of DEMDOLON to select molecules that bind to a protein.

[0052] FIG. 23 shows the anticipated use of DEMDOLON to select molecules that improve delivery and transduction of encapsulated nucleic acids or their derivatives to a specific cell type. In this case it is convenient if barcodes in DEMDOLON are sequences of DNA that encode a reporter protein. A reporter protein can be any protein which is detectable, such as those whose expression can be detected by visual signal (GFP, Luciferase, galactosidase), affinity pulldown (FLAG peptide on the cell surface protein, SpyCatcher receptors), or function (antibiotic resistance). FIG. 24 shows an example of DEMDOLON made by “ prospective barcoding" by transfection of two DNA barcodes inside two cells that have two different molecules on their surface. A) production by retroactive barcoding by transfection of DNA barcode using liposome-based transfection reagent to barcode cell type 1 and cell type 2 (e.g. cell type 1 corresponds to WT CHO cells and it has a lot of terminal sialic acid on glycans in the glycocalyx and low terminal galactose, whereas cell type 2 corresponds to WT CHO cells treated with neuraminidase H and has no terminal sialic acid and high concentration of terminal galactose). (B) Cell mixture containing prospectively barcoded cells. Each cell type has a unique DNA barcode enabling their identification by qPCR or next-generation sequencing upon binding to a target. (C) selection of cell-based DEMDOLON that binds to a specific protein (e.g. target proteins are lectins (1) SNA that binds to sialic acid and (2) PNA that binds to terminal galactose). (D) Detection of binding of cell-based DEMDOLON that binds to PNA protein displayed on beads by qPCR. (E) Representative glycan structures displayed by WT and WT CHO cells treated with neuraminidase H.

[0053] FIG. 25 shows example of DEMDOLON made by “retroactive barcoding by transfection of two DNA barcodes inside two cells that have two different molecules on their surface. A) production by retroactive barcoding by transfection of DNA barcode using liposome-based transfection reagent to barcode cell type 1 and cell type 2 (e.g. cell type 1 corresponds to WT CHO cells and it has a lot of terminal sialic acid on glycans in the glycocalyx and low terminal galactose,- 10 -WSLEGAL\055326\00571\44189453v4whereas cell type 2 corresponds to CMASKOCHO cells and has no terminal sialic acid and high concentration of terminal galactose). (B) Cell mixture containing prospectively barcoded cells. Each cell type has a unique DNA barcode enabling their identification by qPCR or next-generation sequencing upon binding to a target. C) selection of cell-based DEMDOLON that binds to a specific protein (e.g. target proteins are lectins (1) SNA that binds to sialic acid and (2) PNA that binds to terminal galactose). D) Detection of binding of cell-based DEMDOLON that binds to PNA protein displayed on beads by qPCR. E) Representative glycan structures displayed by WT and CMASKOCHO cells.

[0054] FIG. 26 shows anticipated outcome from DEMDOLON screen that identifies a molecular composition that improves delivery of nucleic acid to one cell type. (A) A composition of four DEMDOLON (high mannose, transferrin receptor binder, tri-GalNAc, blank). ( B) The screen uses a mixture of barcoded liposomes (DEMDOLON) and three or more different cell types (for example, hepatocytes, B-cells and red blood cell). Cells that have taken up the DNA become fluorescent and can be sorted from cells that do not contain any barcode. The barcodes are identifiable by NGS for each desirable cell type. (C) Anticipated results observed by sequencing the DNA inside transduced cell types. (D) The same screen can be used in animal models (e.g. wild type mouse). A mixture of DNA barcoded liposome is injected into mice. Animal organs are harvested, and the cells are isolated and sorted for identification of the DNA barcodes associated with each desirable cell type. Further aspects and features of the example embodiments described herein will appear from the following description taken together with the accompanying drawings.DETAILED DESCRIPTION

[0055] The present disclosure relates generally to encoded nanocarrier-based platforms for multiplexed biomolecule display, screening, and profiling of biological targets.I. DEFINITIONS

[0056] Any term or expression not expressly defined herein shall have its commonly accepted definition understood by a person skilled in the art. As used herein, the following terms have the following meanings.- 11 -WSLEGAL\055326\00571\44189453v4

[0057] "Plate assay" refers to an immobilized target on a plate, which is mixed with a ligand and incubated to determine binding. Immobilization of the target is carried out using a high-binding surface microplate or streptavidin microplate, but other possibilities exist and include various types of functionally activated plates for target anchoring. Separation of bound-ligand target complexes from unbound ligands is performed through several washing steps and elution of ligand-target complexes is carried out after the washing procedure.

[0058] Prospectively DNA barcoded carrier" refers to a carrier with which a DNA barcode is associated before a molecule or molecular composition to be displayed, carried, encapsulated, or otherwise presented by the carrier is assigned to that barcode. In some embodiments, the carrier is produced, packaged, assembled, transfected, loaded, or otherwise provided with a DNA barcode before a ligand, biomolecule, or mixture of biomolecules is associated with the carrier, such that subsequent association with the carrier assigns the identity, composition, display density, or functional property of the associated molecule or molecules to the DNA barcode. A prospectively DNA barcoded carrier can be used, as a result, to generate a "prospectively DNA-encoded display library" by preparing multiple carrier populations having different DNA barcodes and subsequently associating different molecules, mixtures of molecules, or surface compositions with the respective carrier populations. In some embodiments, the DNA barcode is contained within, encapsulated by, or otherwise retained by the carrier and does not itself encode a peptide displayed on a surface of the carrier. Accordingly, prospectively DNA barcoded carriers do not require cloned peptide libraries, introduced peptide variable regions, or recombinant display of the molecule being encoded. Suitable prospectively DNA barcoded carriers include viruses from a broad range of viral genera, including viruses that cannot be manipulated to produce surface display or cannot be manipulated efficiently using available recombinant DNA technology. Suitable viruses include bacteriophages and other viruses. Other suitable prospectively DNA barcoded carriers include living cells, virus-like particles, exosomes, liposomes, vesicles, polymeric particles, DNA nanostructures, and other nanocarriers capable of retaining or being associated with a DNA barcode. In some embodiments, the DNA barcode is positioned in a non-translatable region of a viral genome or is provided as a silent barcode within a coding region, such that the barcode does not alter the amino acid sequence of a viral protein and does not produce a new displayed peptide sequence.- 12 -WSLEGAL\055326\00571\44189453v4

[0059] "Pull-down assay" includes an assay where one or the other of a ligand and its target is immobilized or bound to a solid support, such as a bead, to facilitate separation of bound carrierligand-target complexes from unbound ligands or targets. For example, biotin tags can be provided on a target molecule and a biotin binding molecule, such as streptavidin is bound to a bead. Other possibilities may include histidine tagged proteins, and nitrilotriacetic acid-bead; or Fc-fusion of the protein and protein G-bead. Two reactants that are known to form bonds in heterogeneous reaction conditions, known as "bioorthogonal ligations" or "click chemistry" may be used. Examples include well known bioorthogonal pairs such as tetrazine and trans-cyclooctene or cyclooctyne and azide. However, it is understood that these are part of a non-exhaustive list of examples and they are meant to illustrate that other processes that employ specific, strong, complementary covalent or noncovalent interaction may also be suitable to be used for pull-down.

[0060] “Retroactively DNA barcoded carrier" refers to a carrier with which a DNA barcode is associated after a molecule or molecular composition to be displayed, carried, encapsulated, or otherwise presented by the carrier has been established on or in the carrier. In some embodiments, the carrier already comprises, presents, contains, or is associated with a ligand, biomolecule, mixture of biomolecules, cell-surface molecule, surface composition, encapsulated cargo, or functional property. A DNA barcode is then subsequently introduced into, attached to, encapsulated by, genetically associated with, or otherwise retained by the carrier, such that the DNA barcode identifies the preexisting molecule, molecular composition, display density, cargo, phenotype, or functional property of that carrier. A retroactively DNA barcoded carrier can be used to generate a "retroactively DNA-encoded display library" by preparing or obtaining multiple carrier populations that differ in their displayed molecules, encapsulated molecules, surface compositions, cellular phenotypes, or functional properties, and then associating different DNA barcodes with the respective carrier populations before pooling the carrier populations. Suitable retroactively DNA barcoded carriers include living cells, viruses, bacteriophages, virus-like particles, exosomes, liposomes, vesicles, polymeric particles, DNA nanostructures, and other nanocarriers capable of retaining or being associated with a DNA barcode. In some embodiments, the DNA barcode does not encode the displayed molecule and instead serves- 13 -WSLEGAL\055326\00571\44189453v4as an identifying sequence assigned to a carrier population after the displayed molecule, molecular composition, or phenotype has been generated.

[0061] "Barcodes", as used herein, broadly refers to a nucleic acid (e.g. DNA) sequence introduced into any living vessel (e.g., cell, virus, bacteriophage) or non-living vessel or nanocarrier (e.g., liposome, exosome, virus-like particle or protein cage like ferritin, a nano-structured cage made of three- dimensionally folded biomolecules made of protein, DNA or RNA), which has a unique sequence associated with a property or identity of the carrier. The property or identity is thus encoded in the barcode, and the barcode may be sequenced to determine the encoded property or identity. A "silent barcode" is a barcode which does not externally alter the carrier in any discernable manner. For example, the silent barcode is either not expressed or the barcode expression products are phenotypically identical. In some examples, the term refers more specifically to a DNA sequence introduced into a phage, such as within close proximity to a variable region of the phage genome, to allow for simultaneous characterization of these two regions by DNA sequencing. This includes DNA sequences to be clonally introduced at any location within the phage genome, including translationally active and silent regions, auxiliary proteins not used in phage assembly or in sequences excised from phage proteins (e.g. leader peptides). Silent barcodes are described in U.S. Patent No. 10,724,034, the entire contents of which are incorporated herein by reference.

[0062] As used herein, "viruses" (and bacteriophages) include viruses which do not have to originate from a genus known to be amenable to efficient DNA manipulation. The host organism producing such viruses has to only uptake the modified DNA to an extent sufficient for production of at least one modified particle. An example is modification of DNA of Archaeal viruses via synthesis and heterologous manipulation within an E.coli host to introduce redundant codons into the coding regions. Reintroduction of this DNA back to an Archaeal host, albeit with very low efficiency, can produce a set of silent Archaea viruses with identical composition of the coat and different DNA composition in the genome. Once generated, such silent viruses can propagate via reinfection of its host and require no further recombinant DNA technology for scale-up production.- 14 -WSLEGAL\055326\00571\44189453v4I. GENERAL OVERVIEW

[0063] Glycan-binding proteins (GBPs) are tools for deciphering the complex composition of the glycocalyx. Given the importance of glycocalyx, there is a growing interest in developing platforms capable of presenting GBPs in a multivalent and high-throughput fashion to identify subtle differences in the glycocalyx which may be associated with disease states. Lectins are one type, often non-catalytic type of GBP which reversibly bind to specific target carbohydrates without modifying the target.

[0064] For example, lectins like Concanavalin A (Con A), which binds to a-mannose and a-glucose residues, can be used to assess the abundance of oligomannose-type N-glycans on a cell surface. Sialic acid-binding immunoglobulin-like lectins (Siglecs) offer valuable insights for studying sialoglycans involved in immune regulation.

[0065] Despite its significance in drug discovery, phage display is not suitable for presenting complex oligomeric proteins and proteins with post-translation modifications, which includes glycosylated proteins or multi-domain, oligomeric GBPs.

[0066] Display of proteins on surfaces of cells, such as yeast display or mammalian cell display, is attainable. But, display of GBPs in these systems might be particularly problematic due to cis interactions of GBPs and dense glycocalyx coating the surface of all cell types. For example, while sialic-acid binding lectins can be evolved using yeast display, display of mannose-binding lectins on yeast is impractical due to severe cis inhibition between the lectin and mannose-rich glycocalyx.

[0067] As all cells in the three kingdoms of life contain glycans on their surfaces, bacteriophages represent one of the few possibilities for surface display of GBPs with diverse glycan-binding properties.

[0068] Chemical functionalization of prospectively DNA-barcoded phage expands the range of molecules that can be displayed on the phage virion. One-step acylation of N-terminus of the protein pVIII proceeds at mild conditions, enabling incorporation of glycans and other small molecules, but it is not suitable for ligation of proteins. Two-step-reactions first decorate phage with biorthogonal reactive handles, such as ketones, aldehydes, dibenzocyclooctyne (DBCO) or alkynes. Desired functionality on phage can then be installed in a second step with complementary reactive groups (e.g., aminooxy, azide, etc.). However most of these reactions require low millimolar - 15 -WSLEGAL\055326\00571\44189453v4concentration of the substrate. While small molecules can be dissolved at such concentrations, large proteins might not be soluble at these concentrations. From previous trials, reaction conditions that successfully functionalize phage with small molecules were not successful when applied to proteins.

[0069] Several groups demonstrated practicality of enzymatic conjugation of proteins to phage. Sortase-mediated reactions successfully conjugated large multi-domain proteins (including streptavidin) to phages displaying GGGGG (G5) or AAGGGG (A2G4) tag containing peptides. The SpyTag / SpyCatcher has also been previously used to ligate proteins to phage particles. While both sortase-based and SpyTag / SpyCatcher methods are effective, their applicability is constrained to protein that can be expressed with a specific recognition tag.

[0070] Protein conjugation to bacteriophage should preferably use readily available constructs.90% of commercial proteins use His or His / Avitag. In some embodiments, disclosed herein is the synthesis of conjugates on bacteriophage using streptavidin-biotin system. Phages displaying biotinylated coat proteins have been reported and used for conjugation of antibody to streptavidin conjugates. Previous studies have explored streptavidin-labeled gold nanoparticles for electron microscopy or radiolabeled streptavidin / avidin on phage for in vivo SPECT / CT imaging.

[0071] Previous inventions employ cloning of DNA into the genome bacteriophage M13 to introduce the silent barcode, followed by formation of the covalent bond between surfaces of the phage and carbohydrates or covalent conjugation of chemical entities that modify peptides displayed on phage. However, such prior inventions suffer from several limitations. First, they do describe the use of carriers other than an Ml 3 phage, nor how to decorate such carriers without forming covalent bonds, and while they teach “prospective barcoding,” they do not teach “retroactive barcoding.”II. NON-COVALENTLY FUNCTIONALIZED DNA-BARCODED NANOCARRIERS

[0072] In some embodiments, the disclosed platform provides for encoded multivalent liquid lectin arrays. The arrays include nanocarriers containing nucleic acid (e.g. DNA) silent barcodes, and which are functionalized to present one or more lectins, non-covalently bonded on the carrier surface.

[0073] As used herein, a “ nanocarrier" may be any object which can contain or carry a barcode, preferably a silent barcode, and which can be functionalized to display one or more ligands on an accessible surface. This includes not only bacteriophages, but any living object (e.g., a cell from - 16 -WSLEGAL\055326\00571\44189453v4any kingdom of life) or non-living object (e.g., a liposome, nanoparticle, protein, or lipid particle) known to contain genetic material. Suitable nanocarriers may therefore include viruses, cells, liposomes, exosomes, virus-like particles, protein cages, lipid particles, nanoparticles, or synthetic cages capable of holding DNA. In some embodiments, a nanocarrier forms or provides a nanoscaffold on which one or more ligands, bridging molecules, adapters, reactive handles, or combinations thereof are displayed, attached, bound, or otherwise associated. As used herein, “nano” refers to an object or structure having at least one dimension, or an assembled particle size, in the nanometer range, including for example from about 1 nm to about 1000 nm.

[0074] A “ligand” may be any biomolecule or collection of biomolecules that can be displayed by the nanocarrier through a covalent or non-covalent association. For example, the ligand may include a protein, lectin, glycan, peptide, antibody, small molecule, lipid, nucleic acid, or biomolecule, any of which can be chemically modified. A "target" is a molecule or feature which is targeted by the ligand. A heterogenous target is a grouping or collection of at least two different individual targets, such as a glycocalyx, which comprises many different glycans, glycoproteins and / or glycolipids.

[0075] As further used herein, “multivalently-displayed biomolecules” refers to multiple copies of one or more ligands (or biomolecules) that are presented on, attached to, bound to, incorporated into, or otherwise associated with a single nanocarrier. The multiple copies may be copies of the same biomolecule or may include two or more different biomolecules displayed together on the same nanocarrier. In some embodiments, the multivalently-displayed biomolecules are displayed on an accessible surface of the nanocarrier such that the biomolecules can interact with a target through multiple simultaneous or cooperative binding interactions. In some embodiments, multivalent display increases the overall strength or stability of binding between the carrier and a target by permitting more than one ligand-target interaction to occur at the same time.

[0076] In at least one example, a DNA barcode is associated with a nanocarrier to identify a ligand displayed on the nanocarrier, a density of the ligand displayed on the nanocarrier, a composition of ligands displayed on the nanocarrier, or any combination thereof.

[0077] After different nanocarrier populations are pooled and contacted with a target, binding of the different nanocarrier populations to the target can be analyzed. For example recovered DNA can be sequenced to determine which ligands or display formats are enriched. In this manner, the - 17 -WSLEGAL\055326\00571\44189453v4platform converts a mixed population of nanoscale carriers into a sequence-readable display library for profiling interactions with cells, vesicles, tissues, organs, organisms, or purified targets.

[0078] In some embodiments, the nanoscale size of the nanocarriers may reduce steric interference between the carrier and a target relative to larger display formats, thereby permitting displayed ligands to access binding sites on the target and allowing cooperative or synergistic binding interactions to be evaluated, particularly in a liquid format. Nanocarriers having the same or substantially the same carrier composition can also provide a common scaffold background across different ligand populations, such that differences in barcode enrichment are more readily attributed to the displayed ligand, ligand density, or ligand combination rather than to unintended differences in the carrier itself.

[0079] In some embodiments, a DNA-barcoded nanocarrier or other DNA-retaining nanoscale object may be referred to as a DNA-barcoded nanoscale object (referred to herein by the acronym "DBNO"). A DBNO contains, carries, encapsulates, is attached to, or is otherwise associated with a DNA barcode. A DBNO may be converted into, or used as, a DNA-encoded multivalent display of ligands on nanoscale objects (referred to herein by the acronym "DEMDOLON").(i.) Functionalizing the Nanocarrier, including Non-Covalent Functionalization

[0080] In disclosed examples, the nanocarriers may be functionalized with ligands in various ways.

[0081] In some examples, ligands are covalently associated with the carrier surface using complementary reactive pairs, enzyme-mediated ligation reactions, or enzyme-derived covalent coupling systems. Suitable covalent coupling systems include, for example, SpyCatcher / SpyTag, sortase-mediated ligation (e.g., sortase A), haloalkane dehalogenase-based coupling, and other reactions that form a covalent bond between the ligand and the carrier surface.

[0082] In one embodiment, SpyTag-lectins can be displayed on a carrier where the carrier is modified with SpyCatcher ligated to the carrier surface. Spycatcher-displaying bacteriophage is described in Lima et al., 2024, Cell Chemical Biology 31, 1986-2001, the entire contents of which are incorporated herein by reference.- 18 -WSLEGAL\055326\00571\44189453v4

[0083] In some embodiments, the ligands may be attached to a carrier by forming a strong non-covalent interaction with the carrier through the intermediation of a “bridging molecule” (also referenced herein as a universal adapter).

[0084] For example, a carrier coat protein is initially modified with a reactive handle. The reactive handle then interacts non-covalently with a cognate reactive handle on the bridging molecule. The “bridging molecule” further interacts covalently or non-covalently with a cognate reactive moiety or handle on the ligand. This allows different tagged ligands to be displayed on the nanocarrier without requiring each ligand to be expressed as a recombinant fusion product by or on the carrier. The bridging molecule thus requires at least one binding site or reactive moiety which binds or reacts to the carrier coat protein reactive handle, and at least one other binding site or reactive moiety which is available to bind or react to the ligand.

[0085] Preferably, the ligand cognate reactive handle is not reactive with any other functional group on the carrier coat protein.

[0086] In at least one example, the carrier is a filamentous bacteriophage, the reactive handle of the carrier coat protein is biotin, and the bridging molecule is streptavidin or a streptavidin variant which binds to biotin. The cognate binding moiety of the ligand is also biotin. In these cases, the biotin reactive handle is attached to the coat protein by forming an amide bond with lysine or an amino terminus of the carrier coat protein. As the bridging molecule streptavidin is a tetramer, four separate biotin binding sites are available.

[0087] In some embodiments, as exemplified in Figure 1, the carrier may be initially modified with biotin by reacting a biotin reagent, such as a biotin-polyethylene glycol-N-hydroxysuccinimide ester (e.g., biotin-(PEG)4-N-hydroxysuccinimide ester), with surface-accessible amino groups of a coat protein of the carrier. Biotinylation of M13 phage takes place, for example, via the N terminus of g8p or via an exposed lysine residue located at position 8 of g8p. Streptavidin is then bound to the biotin immobilized on the carrier such that one or more biotin-binding sites of the streptavidin remain available to bind a biotinylated ligand. The biotinylated ligand is then contacted with the streptavidin-functionalized carrier, thereby non-covalently associating the biotinylated ligand with the carrier through the streptavidin bridging molecule. In some examples, multivalency is provided by displaying multiple copies of the ligand, the bridging molecule, or both on a single carrier.- 19 -WSLEGAL\055326\00571\44189453v4

[0088] The bridging molecule can be another avidin-based molecule, such as NeutrAvidin or Captavidin. More generally, it can include any other multivalent biotin-binding molecule.

[0089] In some embodiments, the biotinylated ligand can be a glycan-binding protein (GBP), including a lectin, or can be another biomolecule or chemical entity such as a protein, a peptide, an antibody or antigen-binding fragment thereof, a glycan, a glycolipid, a nucleic acid, a small molecule, or any combination thereof. Proteins or peptides can be biotinylated through any suitable technique, including well-known chemical and enzymatic methods. In such embodiments, a biotin moiety on the tagged ligand provides a cognate binding moiety that non-covalently interacts with the bridging molecule, thereby linking the tagged ligand to the nanocarrier.

[0090] It is appreciated, however, that the bridging molecule (e.g., universal adapter) functionality is not limited to streptavidin-biotin binding. For example, a bridging molecule may include dihydrofolate reductase, an antibody, or another protein that binds a small organic molecule or peptide ligand with high affinity (e.g., dissociation constant of 10 nanomolar or lower).

[0091] In some embodiments, preparation of a non-covalently functionalized nanocarrier includes one or more processing steps that improve at least one of ligand loading, reduce aggregation, or remove excess unbound ligand.

[0092] For example, where biotin is used, dialysis can be used to remove residual free biotin or other small molecules that can otherwise occupy binding sites of a bridging molecule, such as streptavidin. In some embodiments, available binding sites of the bridging molecule can be temporarily blocked with a reversible competitor, such as desthiobiotin, to reduce undesired crosslinking or aggregation during preparation. After ligand coupling, excess free tagged ligand, such as free biotinylated lectin, can be removed by purification methods including PEG / NaCl precipitation, gel filtration chromatography, or a combination thereof.

[0093] In at least one example, the nanocarrier provides a multivalent display format. For example, a single nanocarrier can include multiple copies of a reactive handle, multiple bridging molecules, multiple tagged ligands, or a combination thereof. In the streptavidin-biotin example, multiple biotin moieties on a carrier surface can recruit multiple streptavidin molecules, and each streptavidin molecule can in turn bind one or more biotinylated ligands. The resulting carrier can therefore present multiple copies of the same ligand, or in some embodiments multiple different - 20 -WSLEGAL\055326\00571\44189453v4ligands, on a single DNA-encoded carrier. Such multivalent display can increase apparent binding strength through avidity effects and can better mimic multivalent biological interactions, including glycan-binding interactions mediated by lectins or other glycan-binding proteins.(ii.) Prospective or Retroactive Encoding

[0094] The disclosed platform permits one or more surface-displayed features of a nanocarrier to be encoded by a DNA barcode. As noted above, the encoded feature may include the identity of a displayed ligand, a density of the displayed ligand, a composition of different displayed ligands, a ratio of two or more displayed ligands, or any combination thereof.

[0095] In examples involving double barcoding, the DNA barcode may include a "molecule barcode" that identifies the displayed ligand, density, composition, ratio, or a surface feature. The DNA barcode can further include a "unique molecular identifier" (UMI), which can support moleculelevel, carrier-level, or particle-level quantification of recovered carriers. For example, multiple carriers can share a molecule barcode corresponding to the same ligand or surface feature while having different UMIs, such that the carriers can be grouped by encoded feature and individually counted or normalized using sequencing.

[0096] In more detail, molecule barcodes are produced by cloning the molecule barcode library in the phage genome. UMIs are produced by cloning a UMI library in the molecule barcoded nanocarriers. Double barcoded phages are produced separately and modified with different molecules, for example, protein modifications. Pooling these modified libraries together creates a mixed library. Each modification is assigned to one molecular barcode whereas each particle is assigned to one UMI. In one preferred embodiment, the mixed library comprises a "liquid protein array" in which the protein modifications can be traced by sequencing of the molecule barcode and each individual particle can be traced by sequencing and counting the absolute number of UMIs.

[0097] The nanocarriers may be encoded or barcoded "prospectively" or "retroactively".

[0098] In prospective encoding, a DNA silent barcode is associated with the carrier before the ligand is associated with the carrier. The ligand is later assigned to the DNA silent barcode by functionalizing the carrier with the ligand (e.g., non-covalently, as discussed). This approach permits carriers having different DNA silent barcodes to be externally identical or substantially identical before functionalization, while still being distinguishable by sequencing. In some examples,- 21 -WSLEGAL\055326\00571\44189453v4prospective encoding is implemented by introducing the DNA silent barcode into a non-translatable region, into a silent coding region, or into another region that does not alter the ligand-displaying surface of the carrier. Silent barcodes may take advantage of the degeneracy of the genetic code, providing different barcodes which encode for identical translation products.

[0099] By comparison, retroactive encoding provides a complementary mode of operation. In that approach, the ligand or surface feature is established before a DNA barcode is introduced into, carried by, or otherwise associated with the carrier. This is useful where the surface feature is not necessarily designed by the practitioner or is generated before the encoding step. For example, the encoded feature may include a naturally occurring or chemically generated surface feature of the carrier, including a lipid, glycan, glycolipid, membrane protein, chemically modified group, or other molecule accessible at the carrier surface. For example, a cell may naturally present lipids, glycans, glycolipids, membrane proteins, or other surface molecules, and a DNA barcode can then be associated with that cell population to encode the pre-existing surface feature.

[0100] Silent barcoding can be performed using any suitable approach. For example, the DNA barcode can be introduced by genomic insertion, silent coding variation, degenerate codon variation or degenerate sequence variation, plasmid delivery, viral transduction, lipid nanoparticle-mediated delivery, encapsulated DNA, adsorbed DNA, covalently attached DNA, or endogenous sequence variation. In some examples, the encoding preserves the displayed surface feature while allowing the carrier or carrier population to be distinguished by sequencing, qPCR, fluorescence, or combinations thereof.

[0101] Any cell, virus, bacteriophage and other entity that naturally carries a DNA can be manipulated to introduce a random non-functional silent DNA segment somewhere into its genome. The most likely site for such modification is in the region of genome that undergoes no translation and has no significant biological role.(iii.) Liquid Non-Covalent Array (LiNA) Platform

[0102] In one aspect, the present application provides a method of producing a liquid array of ligands on nanocarriers (e.g., modified bacteriophages), which ligands are non-covalently linked to the nanocarrier.- 22 -WSLEGAL\055326\00571\44189453v4

[0103] Nanocarriers contain, carry, or are otherwise associated with a DNA barcode that identifies at least one displayed molecule, a display density of the displayed molecule, or both (e.g., via double barcoding). The displayed molecule can be coupled to the nanocarrier using a non-covalent binding pair, such as a streptavidin-biotin interaction. In other cases, the displayed biomolecule is non-covalently coupled to the nanocarrier using another affinity interaction that links the displayed molecule to the carrier without requiring covalent attachment to a carrier surface molecule.

[0104] Because the identity of the displayed molecule is readable from the DNA barcode, different nanocarrier populations can be pooled, contacted with a target, and analyzed by amplification and sequencing of recovered barcodes. LiNA in this manner provides a sequencing-readable liquid array for profiling interactions between targets and non-covalently displayed biomolecules, including proteins, lectins, peptides, glycans, glycolipids, or other ligands.

[0105] More generally, the disclosed examples further provide process and analytical features that support preparation and use of the display libraries. Reaction conditions may be selected to reduce crosslinking or aggregation during streptavidin-mediated functionalization, including by controlling carrier concentration, streptavidin concentration, ligand concentration, capping conditions, or purification conditions. Aggregate formation may be evaluated by serial dilution and qPCR, and purification may be selected to remove interfering reagents while preserving the binding profile of the carrier library. These features support reproducible preparation of sequence-readable nanocarrier libraries for in vitro, ex vivo, or in vivo selection.

[0106] In some embodiments, the noncovalent liquid array is a Liquid Streptavidin Array (LiSA). In a LiSA embodiment, the nanocarriers are associated with streptavidin or another biotinbinding molecule, and biotinylated ligands are loaded onto the nanocarriers through streptavidin-biotin binding. LiSA provides a streptavidin-biotin implementation of the broader Liquid Non-Covalent Array (LiNA) platform.

[0107] In some embodiments, LiNA may be used to assess binding, uptake, delivery, or other interactions with a variety of targets. Suitable targets may include purified molecules or biomolecules, such as proteins, peptides, lectins, antibodies, receptors, glycans, glycolipids, lipids, nucleic acids, small molecules, cells, viruses, bacteriophages, virus-like particles, exosomes, extracellular vesicles, beads displaying target molecules, tissues, organs, or combinations thereof. The target may be immobilized, displayed on a solid support, presented on a cell surface, present in solution, or present - 23 -WSLEGAL\055326\00571\44189453v4in an in vitro, ex vivo, or in vivo environment. After contacting the target with the DNA-barcoded carrier library, carriers that bind to, associate with, enter, or deliver cargo to the target may be recovered or otherwise enriched, and the DNA barcodes associated with the recovered or enriched carriers may be quantified to identify displayed molecules, carrier compositions, ligand densities, or combinations thereof that interact with the target.III. POOLED SELECTION OF DNA-BARCODED CARRIER LIBRARIES FOR IDENTIFYING TARGET-BINDING LIGANDS

[0108] In some examples, the present method provides a display of barcoded nanocarriers (e.g., prospective or retroactive) which comprises the mixing of N different sets of DNA barcoded carriers, each set bearing a different ligand, or a different density of ligand (e.g., using a LiNA platform).

[0109] In certain embodiments, the different sets of ligands are mixed in equal ratios to simplify downstream analysis, but other related ratios may be implemented. With this mixture that contains N different ligands in the same solution, a one-step selection is performed with a target molecule to identify a subset of AT potential ligands.

[0110] Standard selection methods known in the art may be used, such as a cell panning assay and next generation sequencing of isolated, mixed DNA molecules to identify the nucleic acid codes associated with the ligands which bound to the target.

[0111] The identified AT molecules have some affinity for the target molecule and may be "synergistic binders" or "non- synergistic binders". For example, a collection of m molecules is a set which contains molecules Mi, M2, M3...Mm (i.e, if m=10, you have, Mi, M2, M3, M4,.... Mio). The set of m molecules may be designated as {M}. Thus, there can be sets {M} and subsets {M-Mi} which is the set {M} excluding one set member Mi.

[0112] In this particular embodiment, mixing the liquid protein array having N different proteins, for example, with a cell line of unknown protein binding properties, followed by washing of these cells, enriches M binding proteins (Mi, M2, M3, etc.).- 24 -WSLEGAL\055326\00571\44189453v4

[0113] To test which density of Mi is the best fit to distinguish a cell line with known binder for protein Mi against a reference cell line, a mixed sub-set of all M proteins displayed on different densities and the same set excluding glycan Mi ("M-Mi") is made. A binding assay of these mixtures (e.g. cell panning, plate assay, in vivo panning, pull-down assay) identifies whether protein Mi at a particular density is selective for the target. As the process is a simple mixing, this mixing and pull down can be repeated m times to clearly identify the best protein density.

[0114] A cell panning assay includes a ligand and its target as a mixture when they are incubated on ice, at room temperature or any other temperature. Separation of bound ligand-target complexes from unbound molecules is performed through several washing steps. Washing of unbound ligand can be performed by adding aqueous solutions to cells, spinning the cells down and removing the supernatant. Other methods of washing may simply involve submitting the ligand-target complex to flow cytometry techniques in which case antibodies might be added to the complexes.

[0115] As noted above, identification of nucleic acid codes following a binding assay may involve deep sequencing or next generation sequencing.

[0116] For example, if cells are used in the selection step, the cells may be exposed to vigorous mixing and ribonuclease A and proteinase K treatment to lyse the cells, degrade non-desirable nucleic acid entities, and release barcoded DNA from the carrier. If beads are used in the selection step, the beads may then be exposed to biochemical extraction conditions to segregate DNA material from the bead.

[0117] In all cases, the extracted DNA is then subjected to a polymerase chain reaction which amplifies extracted DNA and attaches new sequences to the extracted DNA, termed "adapter" sequences, that permit sequencing of this DNA using next generation sequencing technologies such as Illumina, or Ion Torrent. Post- processing, PCR or incorporation of adapter sequences are optional steps; one example is the conversion of a phage genome to DNA compatible with Illumina sequencing.

[0118] Another example may include the modification of Illumina sequencing technology to use existing phage DNA as adapter. Alternatively, Illumina adapters may be present in phage DNA. DNA sequences with Illumina adapters may be used directly for incorporation in non-living vesicles or conjugation to any other similar type of nanostructure.- 25 -WSLEGAL\055326\00571\44189453v4

[0119] Both examples of the modifications to the procedure may be used to alleviate the need for PCR-steps or others that introduce "adapter sequences" . The separation of DNA from cells is likely to differ when different carriers are used or different downstream DNA-handling method are used (e.g., PCR with specific reagents). Such separation of DNA from the cells may be readily optimized in accordance with methods known in the art. Following PCR, a suitable "hit" may be identified if a copy number of DNA molecules associated with a particular nucleic acid code exceeds a minimum threshold or ratio.

[0120] In certain exemplary embodiments, the present application provides the use of a "liquid" based format for molecules arrays. In a liquid-based format, multiple molecules attached to freely diffusing silent carriers, such as phages, DNA nanostructures, liposomes, extracellular vesicles and cells can simultaneously bind to a target biomolecule allowing for both hetero and homo- molecule binding co-operatively to occur.

[0121] For a liquid format to work, a method to determine which molecule, for example, are bound to a target is typically required. The present application thus provides, in certain embodiments, a construction of an array using prospective (or retroactive) DNA encoding of molecules; a collection of chemically identical particles subsequently modified with different molecules and then mixed together to form a mixture of N molecules in the same solution.

[0122] With this mixture that contains N molecules in the same solution, one performs a one-step selection — consisting of binding assay and next generation sequencing of isolated, mixed DNA molecules — to identify and quantify an enriched subset of M potential binding molecules displayed at an optimal density. Standard selection methods known in the art may be used. The identified M molecules, in this example, are putatively termed either as "synergistic binders" or "non-synergistic binders".

[0123] A single step then determines which density of any one of the identified ligands, from the subset of {M}, can discern subtle changes in the concentration of a target against a reference. For example, to determine which density of ligand Mi from a set of {M} ligands is the optimal “differentiator”, a new mixture that contains {M} and {M-Mi} components (the latter missing a ligand Mi) is constructed. The enrichment process is repeated for each to identify ligands enriched in the presence or in the absence of the component Mi. The copy number of each ligand pulled from the {M} and {M-Mi} sets are then compared. If a copy number of ligand in two mixtures is significantly - 26 -WSLEGAL\055326\00571\44189453v4different, then the ligand is defined as the optimal “differentiator”. The ligand is the most selective against a target displayed at a certain concentration.

[0124] Molecules for which the enrichment fraction is statistically insignificant between the two experiments are not considered good differentiators and therefore cannot be used to profile subtle changes in the concentration of a target.

[0125] Thus, a library of N ligands is reduced to a subset of M, and a series of selection steps where each member of {M} is omitted in turn provides the differentiating capacity of each member of{M} with each other member of {M}. Unlike screens with separated molecular libraries of molecular arrays that scale as ~N2, this screen requires only M+l screens, where M is a significantly smaller number than N.

[0126] In certain embodiments, the present invention comprises a method to determine the lectin preferences of cell-surface glycans, which are of interest as targets for drug discovery. Other classes of molecules may be similarly examined as the target molecule. Technologies analogous to those of "lectin array" termed protein arrays, peptide arrays, small molecule arrays, nucleic acids and similar arrays are known. They are produced and employed similarly to lectin arrays and may be used in the methods herein with minor or no conceptual modifications.

[0127] In exemplary embodiments, lectins are non-covalently attached to streptavidindisplaying biotinylated filamentous phage M13. Biotinylation of M13 phage takes place, for example, via the N terminus of g8p or via an exposed lysine residue located at position 8 of g8p followed by conjugation to streptavidin. Similar chemical modifications on plant viruses, animal viruses, Archaeal viruses, DNA nanostructures, liposomes, extracellular vesicles or cells may also be used. This application provides for the production of N ligand variants, each silently encoded with a nucleic acid code, of those viruses as N separate preparations. The variants are mixed together to form a mixed library, which may be a liquid array of N ligands. The rest of the selection process - a binding assay of modified virions and next generation sequencing of isolated, mixed DNA molecules - to identify an enriched subset of M potential ligands, is described herein.

[0128] In certain embodiments, examples of a method of the invention may provide the use of targets with known binding affinity to calibrate the system. For example, a liquid array of N lectins are combined with a known calibration target, and the same array is mixed with an unknown target. Using - 27 -WSLEGAL\055326\00571\44189453v4the same cell binding assay for each results in separated cells bearing lectins which bind to the calibration target and the unknown target. Comparison of the copy numbers for hits from each of the control target and unknown target may provide information about the relative binding affinity of the unknown target.

[0129] In certain embodiments, example of a method may be used to measure multivalent and homo-lectin binding, by encoding carriers bearing a lectin at different densities. In one example, an M13 phage carrier contains approximately 2700 copies of g8p per particle, meaning that it is possible to label between 1 and hundreds of lectins per particle. By varying the ratio of lectins in the co conjugation reaction, it is possible to control the average amount of lectins per particle. Thus by tuning stoichiometric ratio of a lectin relative to a control lectin (which should not bind to any glycan) or any other non-binder molecule, such as D-biotin, different densities of displayed lectin may be achieved. By producing several different libraries displaying the same lectin but at different densities with different nucleic acid codes, the effect of multivalent on binding may be measured.IV. LiLA AND / OR LiNA FOR PROFILING THE GLOCYCALYX

[0130] Glycans are critical biomolecules on cell surfaces, with structural changes linked to diseases such as cancer and inflammation. Deciphering glycan complexity in vivo remains a challenge, yet it is essential for developing targeted therapies. Composition of the glycocalyx is traditionally measured using mass spectrometry and slide-based methods, but both approaches require destructive pre-processing steps

[0131] In at least one example application, the platform is applied to liquid lectin arrays (LiLA) and / or liquid non-covalent arrays (LiNA) (e.g., LiSA) for profiling the glycocalyx. LiLA is a multiplexed platform using DNA-barcoded, multivalent lectin-phage conjugates to profile glycans on intact cells in vitro and in vivo. LiLA combines fluorescence-activated cell sorting (FACS) and nextgeneration sequencing for sensitive glycan analysis (Lima, G.M., Cell Biology, 2024).

[0132] LiLA detects subtle glycan changes often missed by conventional methods. For example, mid-valency lectin-phage constructs exhibit ON / OFF-like recognition of sialoglycans, revealing minor differences in glycan density between cell populations. This capability allows LiLA to identify disease-associated glycan signatures, and differentiate glycocalyx profiles across diverse - 28 -WSLEGAL\055326\00571\44189453v4systems, including wild-type and glycan-deficient cell lines, mouse splenocytes, and human peripheral blood mononuclear cells (PBMCs). However, this first-generation LiLA is limited to recombinantly expressed lectins and does not integrate lectins from natural sources and commercially available reagents.

[0133] In addition to LiLA, disclosed examples provide for the use of LiNA, which is a modified version of LiLA. As provided above, LiNA is capable of attaching biotinylated molecules, such as lectins, to phage. This innovation integrates commercially available biotinylated lectins, broadening the applicability of LiLA and enabling the display of diverse biomolecules, including antibodies, peptides, and small molecules, for multiplexed cellular profiling.

[0134] In at least one example, LiLA is combination with LiNA comprising a library of streptavidin-functionalized phages that can display biotinylated lectins or other biotinylated biomolecules to be used to profile glycocalyx features of intact cells. The same carrier format may be combined with covalently functionalized carriers, thereby producing a mixed library that includes different ligand classes or different coupling chemistries in a single assay. The encoded readout allows the composition of the library before and after selection to be compared by qPCR, next-generation sequencing, or another nucleic-acid-based detection method.V. EXAMPLE NANOCARRIERS SUITABLE FOR RETROACTIVE AND / OR PROSPECTIVE BARCODING

[0135] The following examples illustrate how the general framework described above for prospective or retrospective (retroactive) barcoding can be applied across a wide range of nanocarrier types. These examples exemplify that the framework is generally agnostic to the type of molecule being encoded, provided that the carrier can contain, associate with, or otherwise retain a DNA barcode that identifies one or more surface-presented ligands. In each example, the nanocarrier serves as a DNA-containing object whose surface presents one or more ligands, and the resulting populations can be combined and profiled together as a single DNA-encoded display.

[0136] To that end, many artificial compartments are known to contain DNA strands efficiently. Liposomes, polymeric structures, DNA cages, and DNA nanostructures are all known in the art to contain DNA with high efficiency. A collection of large number of such structures can be - 29 -WSLEGAL\055326\00571\44189453v4produced separately to contain strands of different DNA sequence to form “prospectively DNA barcoded carriers” or "retroactively DNA barcoded carriers". A collection of such entities each produced separately to carry different DNA barcodes is “library of prospectively DNA barcoded carriers” or "library of retroactively DNA barcoded carriers".

[0137] Subsequent attachment of biomolecules to said carrier is not related to the nature of incorporated DNA barcode. When biomolecule XI is attached to the carrier 1 that carried DNA barcode Yl, the nature of the biomolecules XI become “associated” with DNA barcode Yl. The process can be repeated to attach and associate biomolecule X2 with barcoded carrier Y2.

[0138] As in previous examples, if there exist N distinct carriers with N DNA sequences in a “library of prospectively [or retroactively] DNA barcoded carriers”, the process can be repeated to associate / attach distinct modification XI-XN to all carriers in such collection and form a DNA encoded library displayed on prospectively DNA encoded carriers.

[0139] As described herein, embodiments of suitable prospectively DNA barcoded carriers typically have a non-translatable region within its genome for DNA encoding. In cases where a non-translatable region is not amenable to modification (for instance, insertion of foreign DNA sequences in the non-translatable sequence results in changes in gene expression), DNA barcodes can placed at any region of a translationally active sequence as silent barcodes, because the silent carriers do not use any variable regions or include any foreign DNA fragment.

[0140] As a result, the nature of the cell, phage or virus used for silent carriers is irrelevant. Thus, in certain embodiments, the carriers do not require virus which is compatible with any display technology, such as viruses which are amenable to manipulation via recombinant DNA technology.

[0141] For example, a class of plant virus is known to be unamenable to display of any foreign sequences because their host, plant cells, proteolytically cleaves nearly all foreign peptide sequences during production of viral particles. Those sequences that are not cleaved can severely interfere with packaging of the particle. These viruses can be still used as silent carriers in accordance with the present application because a silent DNA code can be introduced in a natural protein sequence of regions of DNA that do not produce any sequences. As these changes do not produce any changes in external chemical composition, they are neither excised nor do they typically interfere with the assembly. The virus remains unaltered externally.- 30 -WSLEGAL\055326\00571\44189453v4

[0142] In embodiments of non-living vesicles, there is no DNA actively participating in any biological role, so the nature of the nanostructure is irrelevant to the nature of the barcoded DNA to be introduced. As a result, typically any foreign DNA barcode sequence can be incorporated into nonliving vesicles.

[0143] In certain embodiments, prospectively DNA encoding may include the production of prospectively (or retroactively) DNA barcoded carriers which utilize DNA codes in the encoding DNA of the coat protein themselves, in regions of DNA that do not encode any protein, or in regions of genome that encode an entity that is not present in the assembled particle, such as spliced RNA sequences or post-translationally excised peptide leader sequences.

[0144] This prospectively (or retroactive) DNA encoding permits working not only with fd phage or other phages with a non-translatable region amenable to modification, but with any viruses that can be expressed in laboratory including a large body of known plant, animal and Archaeal viruses, as well as bacteriophages that do not permit display of foreign peptide sequences on their coat protein. Silent variations may be still incorporated in DNA or RNA of these.

[0145] The following non-limiting examples further illustrate how a DNA barcode can be associated with a carrier before or after a surface-presented molecule is established on the carrier.

[0146] (i.) Living Cells

[0147] Living cells exemplify a class of nanocarriers in which the DNA-encoding step can be performed after, rather than before, the ligand of interest is established on the carrier surface (e.g., retroactive barcoding).

[0148] Cells naturally present a complex repertoire of surface molecules, including lipids, glycolipids, glycans, and membrane proteins, and these surface features are typically fixed by the biology of the cell.

[0149] Applied to a simple model system, this principle is illustrated as follows. Where two cells, A and B, present two different lipids (e.g., lipid 1 and 2) on their surface, cell A may be injected with DNA barcode 1 and cell B with DNA barcode 2. The result is a system in which lipid 1 is encoded by barcode 1 and lipid 2 is encoded by barcode 2, and the two cell populations can then be mixed and profiled together as a single DNA-encoded display of lipids.- 31 -WSLEGAL\055326\00571\44189453v4

[0150] (ii.) Liposomes

[0151] As another example, different liposome populations can be retroactively or prospectively barcoded. For example, a first liposome population displaying a first glycolipid can encapsulate DNA barcode A, and a second liposome population displaying a second glycolipid can encapsulate DNA barcode B. When the liposome populations are mixed, the encapsulated DNA barcodes identify the corresponding glycolipid-displaying liposomes, thereby providing a DNA-encoded display of glycolipids that can be profiled in a pooled format.

[0152] (iii.) Viral Protein Carrier

[0153] As another example, viral capsids or viral proteins that assemble around DNA can be prospectively encoded without requiring genetic cloning of the viral genome. A first viral carrier population can be assembled around DNA barcode A and modified to display peptide 1, and a second viral carrier population can be assembled around DNA barcode B and modified to display peptide 2. When the carrier populations are mixed, the encapsulated DNA barcodes identify the corresponding peptide-displaying viral carriers, thereby providing a DNA-encoded display of peptides that can be profiled in a pooled format.

[0154] (iv.) RNA

[0155] RNA-display libraries bearing chemical modifications present a longstanding challenge: the modifications themselves are not encoded by the RNA, and conventional approaches cannot reliably distinguish one modification from another within a single library. Under the present framework, in at least one example, half of an RNA-displayed library may be modified with chemical 1 and conjugated to DNA A, and the other half modified with chemical 2 and conjugated to DNA B, producing a DNA-encoded display of chemical modifications.

[0156] (v.) Spherical Cages

[0157] Spherical cages formed from a synthetic polymer that is capable of holding DNA and amenable to chemical decoration may also be subject to barcoding. For example, a first spherical cage may be loaded with DNA A and modified with chemical 1. A separate second spherical cage may be loaded with DNA B and modified with chemical 2. The two populations are then mixed to form a DNA-encoded display.- 32 -WSLEGAL\055326\00571\44189453v4VI. EXAMPLES

[0158] To gain a better understanding of the invention described herein, the following examples are set forth. It should be understood that these examples are for illustrative purposes only. Therefore, they should not limit the scope of this invention in any way.idin-Based Method For Of Proteins OnFor Cell Surface

[0159] The following examples describe the preparation and characterization of a streptavidinbased phage conjugation platform for profiling the glycocalyx and other cell-surface features.

[0160] In these examples, Ml 3 phage particles are chemically modified to display controlled amounts of biotin on phage coat proteins. The biotinylated phage particles are coupled to streptavidin, and further conjugated to biotinylated glycan-binding proteins (see synthesis, in Example IB).

[0161] The resulting streptavi din-functionalized phage was used to form a liquid streptavidin array (LiSA) for multiplexed glycan-binding analysis of cells having different surface glycosylation profiles. This included analysis using qPCR and next-generation sequencing (Example ID). The LiSA platform was evaluated alone, and in combination with a SpyCatcher-based liquid lectin array (LiLA) to assess compatibility between non-covalent and covalent phage-display formats (Example IE). The examples also examine parameters affecting assay performance, including removal of residual biotinylation reagent (Example 1C), control of streptavidin-mediated aggregation (Example IF), and purification conditions for removing excess lectin (Example 1G).• Example 1A - Synthesis of Lectin-Phage Conjugates Using Streptavidin

[0162] A stable, storable, DNA-encoded library was produced, of defined number of streptavidin proteins on phage. Reaction of M13 phage with biotin-PEG4-NHS ester installs a defined number of biotin molecules on pVIII protein (Figure 1A).

[0163] The number of biotinylated pVIII proteins was easily controlled by controlling the concentrations of biotin and monitoring the reaction by MALDI. Reaction with 3 mM biotin modified 400 out of 2700 copies of p8 protein (Figure IB) (cp-Biotin). The number of biotinylated p8 linearly- 33 -WSLEGAL\055326\00571\44189453v4decreased to 210, 90, 50, 20 as the concentration of biotin-PEG4-NHS decreased from 3 to 0.25 mM (Figure IB).

[0164] Incubation of cp-Biotin with of 10 pM SA containing 10% of fluorescently labeled SA (SA-Cy5) followed by purification of streptavidin-displaying phages (cp-SA) from excess SA by PEG / NaCl precipitation produced pure cp-SA conjugates (Figure 1C).

[0165] Measuring the concentration of SA by fluorescence (Figure ID) and dividing it by the concentration of phage as measured by qPCR (Figure IE) quantified the number of SA copies per phage (Figure IF). MALDI of five distinct phage preparations (N = 5 biological replicates) confirmed that 300 copies of p8-biotin were modified by biotin.

[0166] Fluorescence measurement yielded 300 SA per phage for the same N = 5 replicates. This observation suggested that SA reacts with all available biotins displayed on phage in a ratio of ISA per 1 biotin (Figure IF).

[0167] This example demonstrates that a DNA-encoded phage carrier can be functionalized with a controlled number of streptavidin molecules. By varying the amount of biotinylation reagent used to modify surface-accessible phage coat proteins, the number of biotin sites, and therefore the number of streptavidin molecules displayed on each phage, can be adjusted. The resulting streptavidin-functionalized phage provide a stable and quantifiable intermediate for displaying biotinylated biomolecules in a multivalent format.• Example IB - Biotin-PEG4-Ester Carryover Prevents Binding of Biotinylated Lectins to Phages

[0168] A covalent display of diCBM40 and maltose-binding protein (MBP) (Lima, G. M., 2023). Genetically-engineered U937 cells were used to validate binding of these lectins. For example, diCBM40 binding is reduced in a2,3-CMP-sialic acid synthase knockout (CMASKO) cells compared to wild-type (WT) cells, but MBP does not bind to any glycans on the surface of mammalian cells. Here, LiSA was tested to determine whether it can be used to yield analogous display with analogous performance.

[0169] Biotinylated diCBM40 protein was conjugated to streptavidin-displaying phages (cp-SA) (Figure 2A) and probed the surface of wild-type (WT) and CMAS KO U937 cells. As an unexpected result, binding of cp-CBM to WT was indistinguishable from CMASKO. Phage recovery - 34 -WSLEGAL\055326\00571\44189453v4values were negligible when compared to binding of the same lectins produced using the SpyCatcher-system (Figure 2B). Close inspection of protocol for preparation of cp-biotin phages revealed that not all biotin-NHS-ester has been removed from the reaction (Figure 8A).

[0170] To understand this discrepancy, non-denaturing SDS-PAGE analysis was used; incubation of SA to cp-biotin phage formed a p8-SA band at 60 kDA (Figure 2C), but incubation of cp-SA with biotinylated diCBM40, did not result in any band shift by SDS-PAGE (Figure 2D), which indicated excess of biotin in the reaction (Figure 2E).

[0171] Replacing desalting column with dialysis removed interfering biotin (Figure 8B) and gave rise to band-shift in non-denaturing SDS-PAGE gel upon incubation of biotinylated proteins with cp-SA phage (Figure 2F).

[0172] Accordingly, this example demonstrates that streptavi din-functionalized phage can be used to display biotinylated lectins, but that removal of residual free biotin from the phage biotinylation reaction is important for efficient ligand loading. Initial preparations produced poor diCBM40-mediated binding and failed to show a detectable shift after incubation with biotinylated diCBM40, indicating that residual biotin interfered with available streptavidin binding sites. Replacing desalting with dialysis removed the interfering biotin and restored detectable binding of biotinylated proteins to the streptavidin-displaying phage. Accordingly, this example identifies removal of excess biotinylation reagent as an important preparation parameter for generating functional LiSA carriers.• Example 1C - Analysis of Glycocalyx of Genetically Engineered U937 Cells

[0173] The diCBM40 and peanut agglutin (PNA) lectins, GBPs with mutually exclusive ligands, were probed against WT, CMASKO and genetic knockout of a2,3-sialyltransferase 1 (ST3GallKO) U937 cells.

[0174] cp-S A was mixed with biotinylated diCBM40 and PNA lectins to yield cp- S A-CBM and cp-SA-PNA phages, which recognizes preferentially a2,3-sialic acid and T-antigen, respectively. Inaccessible biotin binding sites were capped with excess D-biotin and phages were used to probe the glycocalyx of genetically engineered U937 cells.

[0175] Encouraged by gel results (Figure 2F), a LiSA displaying diCBM40, PNA and MBP test was formed, and analyzed binding by qPCR (Figure 3A). cp-SA-CBM binding to WT cells was ~1%, decreased by 50-fold for CMASKO and dropped by half on ST3GAL1KO cells (Figure 3B). cp- - 35 -WSLEGAL\055326\00571\44189453v4SA-PNA, on the other hand, binds with greater affinity to CMASKO and ST3GALKO cells, both having higher concentrations of non-sialylated galactosyl-N-acetyl galactosamine residues on the cell surface relative to the WT cells (Figure 3B).

[0176] Mixing of these clones with cp-SA phages capped with biotin as a control (cp-SA- Biotin) and biotinylated Pan-Lectenz, which recognizes a2-3, a2-6, and a2-8 sialoglycans (pan- specific) (Figure 3C) followed by NGS recreated the results obtained by qPCR of cp-SA-CBM, cp- SA-MBP and (p-SA-PNA phage clones (Figure 3D).

[0177] Interestingly, cp-Pan-Lectenz binding to CMASKO was indistinguishable from cp-SA-MBP and cp-SA-biotin controls, lower than cp-SA- CBM. In addition, cp-SA-Pan-Lectenz binds with lower affinity to ST3GallKO, but the difference is less pronounceable than a-2-3 specific a-SA-CBM (Figure 3D).

[0178] This example demonstrates that LiSA can distinguish cell populations having different surface glycosylation profiles using streptavidin-functionalized phage displaying biotinylated lectins. The diCBM40-displaying phage preferentially bound cells having higher levels of a2,3-sialylated glycans, while the PNA-displaying phage preferentially bound cells having higher levels of exposed T-antigen. The observed binding patterns were consistent across qPCR and next-generation sequencing readouts, supporting the use of LiSA for multiplexed glycan profiling. This example further demonstrates that different lectins in the same liquid array can report distinct and biologically meaningful glycocalyx features, while negative controls such as MBP-displaying phage or biotincapped phage show reduced nonspecific recovery.• Example ID - Library Expansion with Spycatcher-Based DNA-Encoded Multivalent Liquid Lectin Array

[0179] SpyCatcher-based DNA-encoded multivalent liquid lectin array (LiLA) (Lima, G. M., 2023), was combined with LiSA. A LiLA composed of diCBM40 (cp-Sc-CBM), MBP (cp-Sc-MBP), Siglec-7 (cp-Sc-Sig7) and inactive R124A Siglec7 mutant (cp-Sc-Sig7R) proteins, was produced. LiLA was probed against WT, CMASKO and carbohydrate sulfotransferase 1 overexpressing (CHST1) U937.- 36 -WSLEGAL\055326\00571\44189453v4

[0180] CHST1 cells are particular relevant given that Sig7 binding to sialic acid is enhanced by 6-O-Gal-sulfation and mutation of the essential R124 arginine residue ablates binding of Sig7 to sialic acid.

[0181] Binding of cp- Sc-CBM and Sc-Sig7 to CHST1 cells was significantly higher than to WT cells, showing approximately 9-fold and 1,500-fold increases, respectively. Sig7R binding was not significantly different from cp-Sc-MBP and cp-blank controls across all cell lines. Interestingly, binding of cp- SA-CBM to CHST1 cells were indistinguishable from WT whereas cp-SA-Lectenz exhibited a 2- fold decrease in binding (Figure 4B).

[0182] However, upon mixing LiLA and Li SA libraries, binding cp- SA-CBM exhibited a 4-fold increase in binding to CHST1 relative to WT cells, and (p-SA-Lectenz showed a similarly enhanced 2-fold greater binding compared to WT (Figure 4C).

[0183] Binding of diCBM40 to CMASKO cells is lower than WT, but above background levels, regardless of the library in which it is displayed (LiLA, LiSA or LiLA+LiSA). In contrast, cp-SA-Lectenz does not exhibit detectable binding to CMASKO cells in either the LiSA (Figure 4B) or LiLA+LiSA libraries (Figure 4C).

[0184] Despite some differences in binding intensity, the combined LiLA and LiSA library exhibited GBP binding profiles comparable to that of either LiLA or LiSA alone. This suggests that mixing the libraries does not diminish the individual performance of the conjugates and maintains similar binding signal without introducing interference or competitive effects (Figure 4C).

[0185]

[0186] Accordingly, this example demonstrates that LiSA can be combined with a SpyCatcher-based LiLA library without substantially impairing the binding behavior of either display format. The combined library (e.g., recombinant and biotinylated GBPs) retained the expected glycan-binding profiles of the displayed glycan-binding proteins. Although some differences in binding intensity were observed between the individual and combined libraries, the combined LiLA and LiSA format preserved the ability to detect biologically meaningful glycocalyx differences. This example therefore supports compatibility between covalent SpyCatcher-based display and non-covalent streptavidin-biotin-based display in a shared multiplexed liquid array.- 37 -WSLEGAL\055326\00571\44189453v4• Example IE - Analysis of <p-SA Phage Aggregates by qPCR

[0187] While multivalent streptavidin offers the biological capability to bridge lectins with DNA-barcoded phages, it also presents a drawback: the crosslinking of multiple phage virions leading to the formation of large aggregates. The size of potential phages aggregates were evaluated by quantifying serial dilutions of each construct by qPCR.

[0188] It was postulated that while samples containing single phage particles would be detectable at concentrations as low as 1-10 phage particles, large aggregates should not be accurately quantified below their respective sizes (Figure 5A).

[0189] A dilution series of biotinylated phages ranging from 100,000,000 to 1 phage particle, was initially prepared. The number of DNA molecules released from each phage (which corresponds to the number of actual phage virions) were quantified by qPCR and the relationship phage particles (logioPFU) versus Cq gave a single straight line (Figure 5B).

[0190] As a “positive” control, leq of streptavidin was incubated for every biotinylated pVIII protein in the solution, which would likely result in crosslinking. Not surprisingly, the number of phages in the solution could not be quantified below 1,000 phage particles, suggesting the presence of phage aggregates of approximately that size (Figure 5B).

[0191] When excess concentration of SA was incubated with cp-biotin phages, crosslinking of phages via SA was abolished (Figure 5B). The aggregate sizes of the lectin-phage conjugates, were then analyzed. It was noticed that all lectin- phage conjugates used to produce LiSA, except cp-SA-CBM, exhibited aggregate sizes ranging from 1,000 to 10,000 phage particles (Figure 5C). The aggregation is likely due to bridging of phages caused by SA to yield particles such as (cp-b) : S A:(cp-b) or by biotinylated lectins (L) to yield particles such as (cp-SA):b-L-b:(cp-SA).

[0192] To better understand this mechanism, the relationship between phage, SA and lectin concentrations with the size of the aggregate, was explored. The number of phage particles was set constant and varied the concentration of phages in the solution (5 x 109 to 5 x 1011 PFU / ml) as well as the amount of SA (5 to 500 pmol) (Figure 6A) (Figure 9). Reactions were incubated for 1 h before measuring the size of the aggregate by qPCR. Sequential addition of SA was also evaluated, with 50 pmol of SA added every 6 min for a total duration of 1 h. As expected, there is less aggregation at lower concentrations of phage and excess of SA (Figure 6A) (Figure 9).- 38 -WSLEGAL\055326\00571\44189453v4

[0193] The same qPCR method was applied to evaluate the size of potential phage aggregates upon incubation with a biotinylated lectin. Given that chemical biotinylation often results in the attachment of multiple biotin molecules to a single protein, biotinylated lectins containing multiple biotins can crosslink with various streptavidin-displaying phages.

[0194] Analysis of biotinylation of MBP by MALDI indicated an average of three biotins per molecule (Figure 6B). The conjugation of cp-SA phages was carried out with 4.5 molar equivalents of biotinylated MBP, i.e. about 4-5 molecules of MBP per molecule of streptavidin displayed on phage. Aggregate size analysis by qPCR indicated that phages aggregate at relatively low concentrations of biotinylated MBP, with roughly 10,000 - 100,000 phage particles per aggregate (Figure 6C).

[0195] By decreasing the concentration of phage and increasing the concentration of biotinylated MBP, we successfully achieve a 100-fold excess concentration of MBP while effectively preventing aggregate formation (Figure 6D).

[0196] Finally, the effect of desthiobiotin on preventing aggregate formation, was evaluated. Desthiobiotin is a biotin analog that binds reversibly to SA with a dissociation constant of approximately 10'13M.241 pM SA with desthiobiotin was pre-incubated, and evaluated the phage aggregate size by qPCR upon incubation with cp-biotin phages. Pre- incubation of SA with 1 mM desthiobiotin, but not at lower concentrations, effectively prevents phage aggregation for 1 h.

[0197] However, overnight incubation of phages with SA pre-complexed with desthiobiotin eventually led to crosslinking (Figure 10A). Control phages pre-incubated with 10 pM biotin do not aggregate (Figure 10A). SDS-PAGE analysis confirmed the formation of the pVIII-SA band at all concentrations of desthiobiotin. However, the band intensity was reduced when 1 mM of desthiobiotin was added and then increased when the complex was subjected to overnight incubation (Figure 10B). In-gel fluorescence corroborated the results obtained by Coomassie-stained SDS-PAGE (Figure 10C).

[0198] In view of the foregoing, this example demonstrates that streptavidin-biotin coupling can cause phage aggregation, and that the aggregation can be detected and reduced by controlling the reaction conditions. Because streptavidin can bind multiple biotin groups, streptavidin-functionalized phage can become crosslinked to other phage, especially when the ligand also carries multiple biotins. The qPCR dilution assay provides a way to estimate whether large aggregates are present. The results show that aggregation depends on the concentrations of phage, streptavidin, and biotinylated ligand,- 39 -WSLEGAL\055326\00571\44189453v4and can be reduced by using suitable excess amounts of streptavidin or ligand, lowering phage concentration, or temporarily blocking streptavidin binding sites with desthiobiotin. Accordingly, this example identifies aggregation control as an important parameter for preparing functional Li SA libraries.• Example IF - Analysis of Purification Methods for Removal of Excess of Lectins

[0199] To prevent unwanted binding of free biotinylated lectin to a lectin-phage construct, two purification methods were evaluated to remove excess of lectins: (1) the standard PEG / NaCl method and (2) size-exclusion chromatography.

[0200] Upon close inspection, it was noticed that cp-SA phages capped with biotin aggregates after PEG / NaCl precipitation (Figure 7A). Given that phages are considerably larger than free proteins and small molecules, we introduced a Li SA sample on a home-made 1-mL long size exclusion chromatography (SEC) column packed with Sepharose resin (Figure 7B).

[0201] To test whether phages can be separated from free proteins, a sample containing a mixture of unmodified blank phages and BSA was passed through the column. SDS-PAGE shows that phages concentrate in earlier elute fractions, peaking at fractions 3-4, whereas BSA elute at later fractions, peaking at fractions 6 and 7 (Figure 7C).

[0202] However, when Li SA containing a mixture of cp-CBM, cp-MBP, cp-PNA, and control phages (cp-biotin and unmodified cp phages) were purified using the same column, it was noticed that only 15% of phages eluted after 1 mL elution using PBS as quantified by qPCR (Figure 7D).

[0203] It is believed that phages containing glycan-binding proteins displayed at high valencies on phage might interact with the Sepharose resin via non-specific binding, leading to fewer phages being eluted. In fact, it was noticed a drop in lectin-decorated phages and increase in the number of control phages (cp-biotin and cp blank phages) in Li SA samples after SEC relative to Li SA samples before SEC, as measured by deep sequencing (Figure 7E).

[0204] Despite losses and drift in Li SA composition as a result of interaction with the SEC column, we decided to probe LiLA against WT U937 cells to compare its binding profile before and after SEC purification, as well as with or without PEG / NaCl purification.- 40 -WSLEGAL\055326\00571\44189453v4

[0205] Quantification of phages recovered from U937 cells by qPCR revealed that LiSA samples exhibited a 70% reduction in binding following SEC purification (Figure 6F). Sequencing of phages eluted from WT U937 cells has shown noteworthy differences between the LiSA samples. Binding of cp-SA-CBM remained 100-fold higher than cp-MBP control with or without PEG / NaCl precipitation.

[0206] This observation persists because the fold change (FC) enrichment of each clone in LiSA is calculated with respect to the specific input composition. Even if purification skews the input, it should be possible to detect the binding as long as a detectable fraction of lectin-modified phages remain available.

[0207] This observation indicates that cp- SA-CBM phage aggregates formed during PEG / NaCl precipitation bind similarly to non- aggregate cp-SA-CBM phages purified by SEC (Figure 6F). However, when LiSA sample is submitted to purification by SEC, it was observed a significant decrease in binding, which could be explained by minor affinity of highly-multivalent cp-SA-CBM phages interact to Sepharose resin (Figure 7G).

[0208] In addition, cp-SA-PNA phages bind 10-fold more strongly to WT U937 cells relative to cp-SA-MBP phages but this interaction not observed when LiSA was not purified by PEG / NaCl precipitation. When SEC purification was carried out cp-SA-PNA, cp-SA-MBP, and cp-SA-biotin exhibited a substantial enrichment over the blank (WT) phage and only a modest difference from cp-SA-CBM phage (Figure 7F).

[0209] This observation may suggest aggregation of these phages via biotin-streptavidin interactions and carryover of inactive phage clones along with active phage clones during the binding to U937 cells. In contract, WT phage that displays no biotin (and no streptavidin) is not included in such aggregates.

[0210] As such, this example demonstrates that removal of excess biotinylated lectin is important for LiSA performance, but that the purification method can affect both phage recovery and library composition. PEG / NaCl precipitation can promote aggregation, while size-exclusion chromatography can separate phage from free protein but may also cause loss or bias of lectindisplaying phage, likely due to interactions with the chromatography resin. Despite these effects, lectin-displaying phage that remain in the library can still produce detectable glycan-dependent - 41 -WSLEGAL\055326\00571\44189453v4binding. Accordingly, this example shows that purification conditions should be selected to reduce free lectin and aggregation while preserving the composition and binding activity of the LiSA library.• Example 1G - Materials and Methods

[0211] The following describes the materials and methods used to prepare, characterize, and evaluate the phage-based conjugates and libraries described in Examples 1 A - IF, above.

[0212] (i.) Materials and General Information.

[0213] Chemical reagents were purchased from Sigma-Aldrich and Thermo-Fischer Scientific unless noted otherwise. NanoDrop TM and QubitTM (ThermoFischer) were used to measure the quantify the concentration of DNA solutions and QubitTM (ThermoFischer) was used to quantify the concentration of protein solutions. Next-generation sequencing was performed at the Molecular Biology Service Unit (University of Alberta) using an Illumina NextSeq500 system. All DNA primers were ordered from Integrated DNA technologies. The U937 were obtained as described by (Jung et al, 2021). Biochemical reagents were purchased from Thermo Fischer Scientific unless noted otherwise. HEPES buffer contains 20 mM HEPES, 150 mM NaCl, 2 mM CaCh, pH 7.4. PBS buffer contains 137 mM NaCl, 10 mM Na2HPO4, 2.7 mM KC1, pH 7.4.

[0214] (ii.) Chemical Modification of Phage Clones with Streptavidin to Build LiLA Components.

[0215] A solution of SDB phage (1013 PFU / ml in PBS) was combined with biotin-PEG4-NHS ester (ChemPrep Cat. 271611) (10 mM in water) to afford a 0.25 - 3 mM concentration of biotin-PEG4-NHS ester in the reaction mixture, which typically yields 1-15% of pVIII modification after 30 min of incubation (cp-biotin).

[0216] After conjugation of biotin, phages were purified using three different methods: 1) ZebaTM Spin desalting column (7K MWCO, 0.5 mL) following the manufacturer instructions, while buffer was exchanged to PBS; 2) Slide-A-Lyzer ® MINI Dialysis unit (Cat. 69550) - 100 pL dialyzed in PBS buffer for 2 h and then dialyzed overnight at 4°C in another PBS buffer; 3) PEG / NaCl precipitation by simply adding 1 / 5 volume of 20% PEG 8,000 / 2.5 M NaCl solution to the reaction mix.- 42 -WSLEGAL\055326\00571\44189453v4

[0217] After 1 hour on ice, the solution was centrifuged at 16,000 g for 10 min, supernatant was removed and the pellet was resuspended in PBS buffer. All chemical reactions were verified and quantified by MALDI-TOF MS as described in previous sections. Solution of 10:1 Streptavidin:Cy5-Streptavidin (Promega Cat. Z7041 and Invitrogen Cat. SA1011, respectively) in PBS was added to the solution of cp-biotin phages to afford a 0.25 - 25 pM concentration of Streptavidin:Cy5-Streptavidin. The solution was further incubated 1 h at room temperature protected from light to yield cp-SA phages.

[0218] To remove excess of streptavidin, 1 / 5 volume of 20% PEG 8,000 / 2.5 M NaCl solution was added and the solution was kept for 1 h on ice. The solution was then centrifuged at 16,000 g for 10 min at RT and the pellet was resuspended in PBS buffer. This procedure was repeated twice.

[0219] (Hi.) Conjugation of Biotinylated Lectin to Phage.

[0220] All conjugations were performed at room temperature for 1 hour. 0.5 - 1.1012 PFU / mL solution of phage and low micromolar concentrations of lectin were mixed in PBS buffer. Protein and phage concentrations were estimated using QubitTM and qPCR, respectively.

[0221] (iv.) Gel Electrophoresis and In-Gel Fluorescence Detection of SA-Cy5.

[0222] Protein conjugation was analyzed on 10% Bis-Tris SDS-PAGE gel with MOPS running buffer. Resolving gel was made using 10% (w / v) acrylamide, 0.27% (w / v) bis- acrylamide, 0.36 M bis-tris pH 6.6, 0.06% (w / v) APS and 0.0025% (v / v) TEMED. Stacking gel was prepared with 4.98% (w / v) acrylamide, 0.13% (w / v) bis-acrylamide, 0.36 M bis-tris pH 6.6, 0.08% (w / v) APS and 0.004% (v / v) TEMED. For MOPS running buffer, 50 mM MOPS, 50 mM Tris, 1 mM EDTA, 0.1% (w / v) SDS and 5 mM sodium bisulfite were used.

[0223] Samples were run at 35 mA. The gel was imaged using a ChemiDocTM Imaging System (BioRad). After imaging, SDS-PAGE was stained with 0.3% (w / v) Coomassie R-250, 10% (v / v) methanol and 10% (v / v) acetic acid for 1 h and distained overnight with 10% (v / v) methanol / 10% (v / v) acetic acid solution.

[0224] (v.) Binding of LiLA and LiSA Components to Glycans on the Cell Surface.

[0225] Cells were aliquoted into FACS tubes (Corning, 352054), which afforded 1 million cells per FACS tube for replicate samples. Cells were centrifuged at 300 g for 5 min and cell pellets were resuspended in incubation buffer (1% BSA in HEPES buffer) at 107 cells per ml.- 43 -WSLEGAL\055326\00571\44189453v4

[0226] Thereafter, phage was added to each FACS tube at 107 PFU and incubated on ice for 1 h. After incubation, the cells were gently vortexed, and wash buffer (3 mL, 0.1% BSA in HEPES buffer) was added to each FACS tube using a serological pipette. The solution was centrifuged at 300 g for 5 min at 4 °C in a swinging bucket rotor. The supernatant was decanted by inverting the FACS tubes and blotting on a Kimwipe.

[0227] Two additional washes were performed: during each wash, the tube was filled with 3 mL of wash buffer, gently vortexed, centrifuged, and inverted to discard the supernatant in the same manner as described above. After the last wash, the pellet was resuspended in 100 pL of wash buffer and subjected to proteinase treatment following protocol described in section “Extraction of phage DNA from cell pellet”.

[0228] (vi.) Extraction of Phage DNA from Cell Pellet.

[0229] Cell pellet from panning experiment containing -106 cells was resuspended with 50 pL O.l mg / mL RNase A in lxPhusion®HF reaction buffer (NEB, Cat. B0518S). Cells were vortexed at maximum speed for 1 min. The suspension was centrifuged at 500 g for 3 min and the supernatant was transferred to a clean EppendorfTM tube. 1 pL of 1% Proteinase K solution was added and the solution was incubated at 56 °C for 10 min. Proteinase K was inactivated after incubation at 97 °C for 3 min. Solution was centrifuged at 16,000 g for 1 min and the supernatant was used as a template for qPCR / PCR.

[0230] (vii.) qPCR protocol.

[0231] 2 pL volume of DNA template solution after the binding procedure was amplified in a total volume of 20 pL with IX of 2X qPCR Master Mix (MBSU, University of Alberta), 0.5 pM forward primer (Pl) and 0.5 pM reverse primer (P2) (Table 1). The 2X qPCR Mastermix (*Dynamite*) used in this study is a proprietary mix developed and distributed by the Molecular Biology Service Unit (MBSU), in the department of Biological Science at the University of Alberta, Edmonton, Alberta, Canada. It contains Tris (pH 8.3), KC1, MgC12, glycerol, tween 20, DMSO, dNTPs, ROX as a normalizing dye, SYBR Green (Molecular Probes) as the detection dye, and an antibody inhibited Taq polymerase.

[0232] The reaction was run in Bio-Rad Cl 000 Thermal cycler CFX96 Real Time System using the following thermocycler settings: (1) 95 °C for 3 min, (2) 95 °C for 10 s, (3) 60 °C for 20 s,- 44 -WSLEGAL\055326\00571\44189453v4(4) 72 °C for 10 s (with picture), (5) repeat steps 2-4 for 39 cycles, and (6) melting point step 65-95 °C (with picture).

[0233] (viii.) PCR protocol and Illumina.

[0234] In the 2-step standard PCR protocol, 2 pL volume of DNA template was amplified in a total volume of 25 pL with 1 x Phusion buffer, 200 pM of each dNTP, 0.5 pM forward primer (Pl), 0.5 pM reverse primer (P2) (Table 1), 5% (v / v) DMSO and 0.8 U Phusion High-Fidelity DNA polymerase (NEB, M0530S).

[0235] Cycling was performed using the following thermocycler settings: (1) 98 °C for 3 min, (2) 98 °C for 10 s, (3) 50 °C for 20 s, (4) 72 °C for 20 s, (5) repeat steps 2-4 for 30 cycles and (6) 72 °C for 1 min. The product from 1st PCR step was used in the next PCR amplification step to prepare samples for Illumina sequencing.

[0236] The protocol was adapted from Sojitra et al 12 with minor modifications. 2 pL volume of DNA template from first-step PCR was amplified in a total volume of 25 pL with 1 x Phusion buffer, 200 pM of each dNTP, 0.4 pM forward barcoded primer (P3), 0.4 pM reverse barcoded primer (P4) (Table 1), 5% (v / v) DMSO and 0.5 U Phusion High-Fidelity DNA polymerase (NEB, M0530S). Cycling was performed using the following thermocycler settings: (1) 95 °C for 3 min, (2) 95 °C for 10 s, (3) 58 °C for 30 s, (4) 72 °C for 20 s, (5) repeat steps 2-4 for ten cycles and (6) 72 °C for 5 min.

[0237] PCR products were quantified with a 2% (w / v) agarose gel in Tris-borate-EDTA buffer at 100 V for ~35 min using a 1 Kb Plus DNA ladder. PCR products that contained different indexing barcodes were pooled, allowing 40 ng of each product in the mixture. The mixture was purified using Nucleospin® Gel and PCR clean-up kit (Macherey-Nagel # 740609), quantified by Qubit (Thermo Fisher), and sequenced using the Illumina NextSeq paired-end 500 / 550 High Output kit version 2.5 (2 x 75 cycles). Data was automatically uploaded to the BaseSpace Sequence Hub. The processing of data is described in the section “Processing of Illumina Data” (see below).Table 1 - Sequence of Oligos UsedName SequencePl TTTTGGAGATTTTCAACGTG [SEQ ID NO: 1]P2 CCCTCATAGTTAGCGTAACG [SEQ ID NO: 2]P3 CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCT- 45 -WSLEGAL\055326\00571\44189453v4GCTGAACCGCTC TTCCGATCTNNNNTTGGAGATTTTCAACGTG [SEQ ID NO: 3]P4 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCT ACACGACGCTCTTCC GATCTNNNNACAGTTTCGGCCGA [SEQ ID NO:4] _

[0238] (ix.) General Data Processing Methods.

[0239] In NGS sequencing, the reads with length above or below 96 base pairs, were systematically excluded from all analyses. NGS Reads that could not be mapped to specific DNA-barcodes or their neighbors (Hamming distance = 1) were excluded from all of the analyses.

[0240] Data analysis was performed in Python and testing differences for significance in LiLA / LiSA data was performed as Mann-Whitney U test analyses of phage-displayed libraries based on fold changes (FC) enrichment analysis.

[0241] The FC-analysis assumed that the group of either cp-SA-MBP or cp-blank phages does not bind to test samples. All other lectin FC ratios were normalized to MBP or cp-blank. Core processing scripts are available as part of the supplementary information (Data SI) or on GitHub.

[0242] To assess the significance of a lectin binding in a specific experiment the FC analysis of the levels of the DNA barcode associated with that lectin in “test” sets of DNA reads was compared to the levels of the same barcode in naive library or “input” data set.

[0243] Reads in the input dataset were averaged when more than one input sample was sequenced. Means of input were not used to calculate the statistics of the data. Prior to FC-analysis, “test” and “input” data sets were retrieved from a cloud-based server repository as tables of DNA sequences, and raw sequencing counts / DNA reads that could not be mapped to any entries in the LiLA dictionary were discarded.

[0244] (x.) Processing of Illumina Data.

[0245] The processing of FASTQ files downloaded from BaseSpace™ Sequence Hub to reads and frequencies of lectins were performed as previously described. (Sojitra, M., et al , 2021) (Lima,- 46 -WSLEGAL\055326\00571\44189453v4G. M, et al, 2023). A LiLA-specific lookup table was used to convert the identified SDB to lectin and display density (Table 2).

[0246] Translated files with raw DNA reads, raw counts, and mapped lectins were uploaded to the https: / / 48hd.doud / . server. All LiLA sequencing data is publicly available at this location. Each experiment has a unique alphanumeric name (e.g., 20250404- 1728LXooBO-GL, see Table 2).Table 2 - List of LiLA and LiSA Mixtures UsedLibrary Composition Naive Composition Experimental DataDetailsLN.xlsx SA-CBM 20240229- 20240229- SA-MBP 1728LNooBO-GL 1728LNuaaYX-GLSA-PNA 20240229- SA-Lectenz 1728LNubaYX-GLSA-Biotin 20240229- 1728LNufaYX-GLLV.xlsx Sc-CBM 20250404- 20250404- Sc-MBP 1728LVooBO-GL 1728LVuaaYX-GLSc-Sig7 20250404- Sc-Sig7R 1728LVubaYX-GLBlank 20250404- 1728LVucaYX-GLLX.xlsx LN + Blank 20250404- s1728LXooBO-GLLY.xlsx LV + LX 20250404- 20250404- 1728LYuaaYX-GL 1728LYooBO-GL 20250404- 1728LYubaYX-GL20250404- 1728LYucaYX-GLLT.xlsx SA-CBM 20240812- 20240812- 1728LTuaaYX-GLSA-MBP 1728LTooBO-GL 20240812- 1728LUuaaYX-GLSA-PNA 20240812- SA-Biotin 1728LUooBO-GLBlank

[0247] (xi.) Size-Exclusion Chromatography.

[0248] Glass wool was placed inside a 1 mL disposable plastic syringe to make a filter. The syringe was filled with a suspension of Sephacryl S500HR resin (Cytiva 17-0613-01). 3 mL of PBS buffer was added to equilibrate the column. After equilibration, 100 pL sample was loaded onto the- 47 -WSLEGAL\055326\00571\44189453v4column and 1 mL of PBS was carefully added to elute the phages. The samples were collected in -100 pL fractions.Example 2 - UMI-Encoded Liquid Non-Covalent Arrays for Multiplexed Biomolecule Display and Screening

[0249] Building on the streptavidin-based phage conjugation structure described in Example 1, the following example describes the preparation and use of a silently encoded phage-based liquid non-covalent array platform. This library may be used for multiplexed biomolecule display and screening.

[0250] In these examples, phage libraries from Example 1 are further engineered to be "double barcoded" such as to include "molecule barcodes" and distinct "unique molecular identifiers" (UMIs). In this manner, attached biomolecules, display densities, and individual phage particles can be identified or quantified by sequencing (Example 2A).

[0251] The example further describes coupling of streptavidin and biotinylated biomolecules to filamentous phage using the streptavidin-biotin architecture described above (Example 2C), optimization of reaction conditions to reduce streptavidin-mediated aggregation (Example 2B), and encoding of different ligand densities using silent carrier phage (Example 2D).

[0252] The stability and sequencing readability of incorporated UMIs are further evaluated by deep sequencing (Example 2E).

[0253] The resulting liquid non-covalent array (LiNA) is evaluated for cell-based screening using lectins against genetically engineered U937 cells. It is further applied to non-covalent display of glycans and peptides, including in vivo screening applications (Example 2F).

[0254] Accordingly, this example demonstrates that silently encoded phage carriers can be used to generate sequencing-readable non-covalent arrays for profiling biomolecular interactions across multiple classes of displayed ligands.

[0255] Unless otherwise indicated, the methods and materials described in Example 1G apply to the discussion in Example 2.- 48 -WSLEGAL\055326\00571\44189453v4Example 2A - Cloning and Isolation of UMI phage Library

[0256] A UMI-silently encoded phage library was cloned using a 2-step cloning procedure. The molecule barcode region (Figure 11 and Figure 15 A) was introduced into fthl using PCR amplification followed by restriction enzyme digestion and T4 ligase DNA ligation (NEB).

[0257] The insert fragment containing the molecule barcode and an RNA-sequencing compatible capture sequence was produced by annealing oligo "1": 5’ GTT TCT TGC TAG CTG GGG CAA ACT GCA CTG CCA GCG NNN NNN NNN NAG CTG TTG CGC TTT AAG GCC GGT CCT AGC AAT GCT CGA GAA AGA AAC - 3’ [SEQ ID NO: 5], and oligo "2": 5’ GTT TCT TTC TCG AGC ATT GCT AG - 3’ [SEQ ID NO: 6],

[0258] dsDNA insert fragment was produced by extending oligo 2 using Q5 polymerase. dsDNA insert fragment and fthl vector were treated with restriction enzymes Nhel and Xhol and then gel purified. Ligation was then carried out using T4 DNA polymerase according to the manufacturer instructions.

[0259] The resulting ligated DNA was transformed into E.coli TGI and grown overnight at 30°C to allow phage library expansion. The overnight culture was then centrifuged to separate bacteriophage from host cells. The host cell were then processed by MiniPrep kit to extract dsDNA for sequencing.

[0260] To clone the UMI onto the barcoded dsDNA library, phage clones were isolated from the first cloning step and extracted their dsDNA using a Miniprep kit. The UMI fragment containing an adapter sequence for Illumina sequencing (Figure 11 and Figure 15 A) was produced by annealing oligo "3": 5’ GCA GTG CAA CTC ANN NNN NNN NNN NNN NT A ATG CAG AGA TCG GAA GAG CAC ACG TCT GAA CTC CAG TCA CGC TAG CAA GAA AC - 3 ’ [SEQ ID NO: 7], and oligo "4": 5’ - GTT TCT TGC TAG CGT GAC TGG AG - 3’ [SEQ ID NO: 8],

[0261] dsDNA insert fragment was produced by extending oligo 4 using Q5 polymerase. dsDNA UMI fragment and barcoded fthl vector were treated with restriction enzymes Nhel and BtsI and then gel purified.

[0262] Ligation was then carried out using T4 DNA polymerase according to the manufacturer instructions. The resulting ligated DNA was transformed into E.coli TGI and grew overnight at 30°C to allow phage library expansion. The overnight culture was then centrifuged to separate bacteriophage - 49 -WSLEGAL\055326\00571\44189453v4from host cells PEG precipitated to concentrate released phage. PEG precipitated phage were resuspended in 1 % PBS 50% Glycerol and stored at -20°C.

[0263] The molecule barcode results in 410 possible sequence combinations, whereas the UMI region results in 415 possible sequence combinations. Monoclonal silently encoded phage was isolated by plaque isolation. Phages were plated at a density of 100 plaque per plate and individually picked. Phage isolates were picked, grow and sequenced.

[0264] To increase the accuracy of next generation sequencing only barcodes that are greater than hamming distance 3 apart, hamming distance is defined as the number of changes that needed to convert a string from one sequence to another, where retained. Unique barcoded phage was amplified and concentrated using PEG precipitation.

[0265] Figure 11 provides a scheme related to the construction of double barcoded phage downstream the tetracycline gene (Ter).

[0266] Table 3 provides examples of DNA sequences of phage isolates containing molecule barcodes as described in Figure 11. Molecule barcode is a 10 base pair long sequence, while the UMI region contains a library of 15 base pair long sequences upstream the molecule barcode. The diversity of UMI sequence is dictated by the size of the phage library generated after the transformation.Table 3 - DNA Sequences of Phage Libraries ContainingMolecules Barcodes and UMIs (as Described in Figure 11)Modificat Phage UMI Molecule Barcodeion particle1 1 ATGCCGTAGCATCGA ATGCTAGCAT[SEQ ID NO: 9] [SEQ ID NO: 10]1 2 TCGATACGCGTACAG ATGCTAGCAT[SEQ ID NO: 11] [SEQ ID NO: 12]1 3 GATCGATCGATCGAT ATGCTAGCAT[SEQ ID NO: 13] [SEQ ID NO: 14]2 4 CCGATAGCTAGCTAG CCGATAGCTA[SEQ ID NO: 15] [SEQ ID NO: 16]2 5 ATCGTAGCATGCATG CCGATAGCTA[SEQ ID NO: 17] [SEQ ID NO: 18]2 6 GCTAGCTAGCTAGCT CCGATAGCTA[SEQ ID NO: 19] [SEQ ID NO: 20]3 7 TAGCATGCTACGTAG TAGCATGCTA[SEQ ID NO: 21] [SEQ ID NO: 22]3 8 CGTAGCTAGCTAGCT TAGCATGCTA- 50 -WSLEGAL\055326\00571\44189453v4[SEQ ID NO: 23] [SEQ ID NO: 24]3 9 CATGCTAGCTAGCTA TAGCATGCTA[SEQ ID NO: 25] [SEQ ID NO: 26]• Example 2C - Coupling of Streptavidin and Biotinylated Protein to Filamentous Phage.

[0267] As described in Example 1 A, filamentous phage can be chemically modified on pVIII coat proteins using a biotin-(PEG)4-N-hydroxysuccinimide linker, and then coupled to streptavidin to generate streptavidin-displaying phages. The following example applies the same streptavidin-biotin conjugation architecture to silently encoded phage libraries carrying molecule barcodes and UMIs. This thereby enables the encoded phage carriers to bind biotinylated proteins or other biotinylated biomolecules for formation of a liquid non-covalent array (LiNA).

[0268] Particularly, the coupling of biotinylated molecules to filamentous phage virion was accomplished using a three-step procedure and a biotin-(PEG)4-N-hydroxysuccinimide linker (Biotin-NHS) (Figure 12 and 16A).

[0269] Figure 16A shows generally the scheme of chemical ligation strategy used for incorporation of biotin onto pVIII protein of the phage (1st step) followed by non-covalent binding to streptavidin (2nd step). Streptavidin-displaying phages are amenable for binding to any biotinylated biomolecule (3rd step) to create a liquid array of any biomolecule entity. Each reaction can produce a phage that contains modified and unmodified p8 proteins.

[0270] Figure 16B shows chemical schematics of the amino acid sequence of p8 protein, their modification by biotin-(PEG)4-N-hydroxysuccinimide linker (biotin-NHS), and ligation of streptavidin to biotin- modified p8 protein.

[0271] Firstly, phage library carrying a single molecule barcode and -106 UMIs are reacted with the linker via the N-hydroxysuccinimide group. This linker covalently attaches to the phage virion by the major virion coat protein pVIII via the N terminus of pVIII polypeptide sequence. The phage carrying the crosslinker then reacted with streptavidin followed by incubation with any biotinylated molecule, linking the biomolecule to the phage virion. To optimize this chemistry high concentrations of streptavidin were used.

[0272] Phage were first incubated with 5x equivalents of biotin-(PEG)4-N-hydroxysuccinimide ester for 60 minutes (the equivalents were calculated with respect to the molarity - 51 -WSLEGAL\055326\00571\44189453v4of the total pVIII protein per phage. For example: 1013phage contains 2700* 1013pVIII proteins per 1 mL, which (2700* 1013*103) / (6.02*1023) = 45 * 10'6molar concentration of pVIII. Streptavidin was then added to this mixture and incubated for 1 h.

[0273] The biotinylated reaction was dialyzed to remove unreacted biotin-NHS and the streptavidin-phage mixture was purified by PEG / NaCl precipitation to remove excess of streptavidin. Biotinylated phage was analyzed using MALDI-TOF using sinapinic acid as the matrix.

[0274] Figure 16C shows characterization of conjugates via MALDI. MALDI detects unmodified p8, and biotinylated p8 protein. The ratio of the peaks in MALDI permits characterization of incomplete reactions and it allows estimating the final densities of biotin on phage. The peak height of the m / z ratio of the target peaks for unmodified pVIII (mol wt 5239) and linker-phage (mol wt 5710) was found to be proportional to stoichiometry of the linker and phage used.

[0275] Phage pVIII protein contains two solvent exposed amino groups available for modification (Figure 16B). The first one is the N-terminal amino group and the second one is lysine (eighth from the N-terminal). Given the relatively low concentration of biotin-NHS used, one could only detect modification in the N-terminal amino group (Figure 16C).

[0276] To quantify the number of streptavidin copies per phage, biotinylated phages are reacted with excess of streptavidin containing 10% streptavidin-Cy5 (streptavidin: streptavidin-Cy5 9:1).

[0277] The scheme is depicted in Figure 16D. Streptavidin-Cy5 is a fluorescently labeled streptavidin and enables quantification of number of streptavidin copies in the solution by fluorescence. After Ih incubation in PBS buffer, streptavidin-phage mixture is purified twice by PEG / NaCl precipitation to remove unbound streptavidin.

[0278] Phage precipitate is resuspended in PBS buffer and number of streptavidin in solution is quantified by fluorescence. Number of phage particles is quantified by qPCR. Number of streptavidin molecules per phage is calculated by dividing the number of streptavidin molecules by the number of phages.

[0279] Figure 16E shows that the number of streptavidin copies matches the number of biotin molecules quantified by MALDI. Figure 16F shows that streptavidin bound on phage can be analyzed by non- denaturing SDS-PAGE.- 52 -WSLEGAL\055326\00571\44189453v4

[0280] In the third step of coupling of biotinylated protein on phage, streptavi din-displaying phages are reacted with excess of biotinylated protein for 1 h in PBS buffer. Unoccupied streptavidin binding sites are “capped” with 10 pM D-biotin for 30 min in PBS buffer. Figure 16G shows that proteins bound on streptavidin-displaying phages can be analyzed by non-denaturing SDS-PAGE.• Example 2B - Quantification of Serial Diluted Samples of Streptavidin-Displaying Phages by qPCR for Estimation of Aggregate Size

[0281] As described previously in Example IE, streptavidin-displaying phages can form aggregates when multivalent streptavidin-biotin interactions bridge multiple phage particles. The following example further applies the qPCR-based aggregate-size analysis described above to identify reaction conditions that favor formation of single-particle streptavidin-displaying phages for use in the silently encoded phage library platform.

[0282] Particularly, special reactions conditions are required for generation of single-particle streptavidin-displaying phages. To prevent cross-linking, one must ensure that there is excess of streptavidin relative to biotinylated phage and that phages are diluted enough to prevent the formation of aggregates. Sizes of eventual phage aggregates are estimated by qPCR. To test the ideal concentrations of phage and streptavidin to be used that can prevent formation of phage aggregates, the following procedure was used.

[0283] Each of three phage concentrations (5xl09, 5xl010and 5xl0nPFU / ml) were reacted with each of the four amounts of streptavidin (5 pmol, 50 pmol, 50 pmol by adding 5 pmol of streptavidin progressively, ten times, and 500 pmol of streptavidin) (Figure 6a). Amount of phage used was fixed to 5xl09PFU for every reaction. Therefore, decreasing concentrations of phage represents increasing reaction volumes, going from 20 pL (for 5xl0nPFU / ml of phage ) to 2,000 pL of reaction volume (for 5xl09PFU / ml of phage). 5 pmol of streptavidin corresponds to 1 equivalent of streptavidin per number of biotinylated p8 protein (i.e. 5xl09PFU phage contains 5 pmol of biotinylated p8 protein); 50 pmol corresponds to 10 equivalent of streptavidin, and 500 pmol corresponds to 100 equivalent of streptavidin.

[0284] Serial dilutions of each reaction condition were performed for quantification of aggregate size by qPCR. Phages were initially diluted to a concentration of 5xl010PFU / ml or 5xl09PFU / ml. 5xl010PFU / ml contains 108 PFU per 2 pL. 2pL is the standard volume of sample used for - 53 -WSLEGAL\055326\00571\44189453v4qPCR. Phages were diluted 10-fold in PBS up to 5xlO2PFU / ml or 1 PFU per 2 pL. Phage samples were submitted for qPCR using the following procedure: 2 pL volume of phage sample was amplified in a total volume of 20 pL with 1* 2X qPCR Master Mix (MBSU, University of Alberta), 0.5 pM forward primer 5’ TTTTGGAGATTTTCAACGTG - 3’ [SEQ ID NO: 27] and 0.5 pM reverse primer 5’ - CCCTCATAGTTAGCGTAACG - 3’ [SEQ ID NO: 28],

[0285] The reaction was run in Bio-Rad Cl 000 Thermal cycler CFX96 Real Time System using the following thermocycler settings: (1) 95 °C for 3 min, (2) 95 °C for 10 s, (3) 60 °C for 20 s, (4) 72 °C for 10 s (with picture), (5) repeat steps 2-4 for 39 cycles, and (6) melting point step 65-95°C (with picture). A calibration curve was created for every reaction condition. The calibration curve is created by plotting the amount of phage in the reaction mix in the x axis (logio [phage]) and the resulting Cq value in the y axis. Size aggregate is equal to N, where N is the amount of phage in the reaction mix given that the Cq difference between N and N / 10 is greater or equal to 5.• Example 2D - Encoding Different Multivalent Density of Ligands Using Silent Carriers

[0286] The density of display on the phage particles can be encoded. Figure 13 provides a description of the effect of controlling stoichiometric ratio of 2 lectins to produce particles displaying the same lectin at different densities.

[0287] A mixture of different silent carriers is produced where each silent carrier phage is conjugated with a different lectin or a different density of lectins as described in Figure 13. Pooling the mixture together generates the mixture in which each lectin and each different lectin density is associated with a unique carrier, identifiable by its silent barcode.

[0288] As shown in Figure 13, Pl is associated with protein 1, at a density of 4 protein molecules per phage particle. P2 is associated with protein 1 and protein 2, at a density of 43 protein 1 molecules per phage particle and 1 protein 2 molecules per phage particle. P3 is associated with protein 1 and 2, but at a density of 2 protein 1 molecules per phage particle and 2 protein 2 molecules per phage, while P4 is associated with protein 2 at a density of 4 protein 2 molecules per phage particle.

[0289] The density and identify of phage particles can also be encoded by more than one silent carrier phage. For example, a mixture of 5 silent carrier phages is produced where the 5 silent carrier phages are conjugated to a particular molecule at a particular density.- 54 -WSLEGAL\055326\00571\44189453v4Example 2E - Demonstration of Stable Incorporation of UMIs on fd Phage Genome using Deep Sequencing

[0290] To demonstrate that the modification of the phage genome with foreign non-translatable random DNA sequences yield uniform distribution of nucleotides (non-biased phage amplification), sequencing of a library of a 10 base pair long UMI fd phages was conducted with Illumina forward sequencing primer 5’ - CAA GCA GAA GAC GGC ATA CGA GAT CGG TCT CGG CAT TCC TGC TGA ACC GCT CTT CCG ATC TNN NNA GGA CCG GCC TTA AAG C3’ [SEQ ID NO: 29] and Illumina sequencing reverse primer 5’ - AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC TNN NNG ACG TGT GCT CTT CCG ATC - 3’ [SEQ ID NO: 30], Primer forward anneals to the RNA-sequencing capture sequence and primer reverse anneals to the TruSeq region (Figure 15 A). N denotes any nucleotide.

[0291] Figure 16H shows distribution of nucleotides at a 10-bp long UMI region. Height of the base represents the proportion of the base relative to the other 3 nucleotides.

[0292] Figure 161 shows the total number of unique reads detected by deep sequencing (N = 3135, x axis) and the total number of reads associated with each of the 3135 unique UMI reads (y axis). The number of unique UMI reads dictates the number of phage particles that can be quantified. Increasing the efficiency of DNA library transformation increases the number of unique reads detected by Illumina sequencing, and consequently the number of total individual phage particles that can be quantified.• Example 2F - Demonstration of Cell Based Screening with Liquid Non-Covalent Array (LiNA)

[0293] LiNA can be used to assess the lectin binding property of live whole cells. To demonstrate this, the LiNA array was panned against myeloid leukemia U937 cell lines that possess distinguishable glycosylation profiles: wild-type (WT), cytidine monophosphate N-acetylneuraminic acid synthase deficient (CMASKO), carbohydrate sulfotransferase 1 overexpressing (CHST1) and ST3 beta-galactoside alpha-2, 3-sialyltransferase 1 deficient (ST3GAL1KO) U937 cells.

[0294] The U937 cells were obtained as described by (Jung et al, 2021). LiNA was composed of 8 lectins plus a biotin control. diCBM40 is an engineered recombinant lectin that robustly bind to a2-3 and a-2-6 sialosides, demonstrating notably higher affinity for the former; MBP is a maltose- - 55 -WSLEGAL\055326\00571\44189453v4binding protein that should not bind to any mammalian cell line; PNA binds preferentially to the T antigen; ECL and UEA binds preferably to galactose-containing sugars, ConA binds to mannose, StcE binds to mucins, and EndoN to polysialic acid.

[0295] To do this experiment, Log phase cells were resuspended at 1 x 106cell / mL in Hepes Buffer (20 mM HEPES pH 7.4, 150 mMNaCl, 2 mM CaCl, 1% BSA. L mL aliquot of cells were then pelleted (300 g / 5 min) and resuspended in 200 pt of HEPES Buffer containing 1 x 108pfu of LiGA phage.

[0296] Cells were then incubated for 1 hour on ice. Cells were then washed 3 times using 3 mL of Hepes Buffer containing 0.1% BSA and resuspended in 50 pL of lx HF buffer with 0.1 mg / ml RNaseA. Cells were vortexed for 1 min at maximal speed and then pelleted (500 g / 3 min). Supernatant was then transferred to a 1.7 mL tube and 1 pL of 1% Proteinase K was added. Cells were incubated for 10 min at 56 °C for 10 min, and then boiled for 3 min followed by centrifugation at 16,000 g for 1 min to remove any remaining cell debris. The supernatant was then transferred into PCR tubes containing PCR reaction mixture to prepare amplicons for Illumina Sequencing. NGS analysis yielded observations parallel between LiNA and binding of individual lectins measured by flow cytometry (Figure 14).

[0297] Figure 17 shows that LiNA can be tested against murine cells both in vitro and in vivo and analyzed by NGS. In these examples, a mixture containing diCBM40, genetically engineered Pan-Lectenz lectin, PNA and MBP lectins non-covalently attached to phage was created. The mixture also contains covalently attached diCBM40, MBP and Siglec7 proteins. Covalently displayed and non-covalently displayed proteins were observed, which exhibited distinct in vivo performances upon injection of the same library in mice.

[0298] As an orthogonal example of biotinylated M displayed on LiNA, G2 and Man9 sugars (both natural and fluorinated - 2F, 6F, and 2,6F) were included, and which were modified with biotin at the reducing end (Figure 15). Non-covalent LiNA displays of glycans were combined with previously reported Liquid Glycan Array containing G2, Man9 and a library of complex N-linked glycans with an azido linker covalently attached to phage.

[0299] NGS uncovered binding preference of chemically modified 2F-Man9 for ConA, preferential binding of natural Man9 to WT DC-SIGN, and binding of both Man9 and 2F-Man9 to - 56 -WSLEGAL\055326\00571\44189453v4DC-SIGN mutants. No differences were observed among Man9 variants in their binding to live cells expressing DC-SIGN (Figure 15). Assays performed in such a mixture observed no differences in binding behavior of G2 glycan displayed at similar densities on covalent LiGA vs. non-covalent LiNA.

[0300] LiNA can display peptide and tested in vivo as demonstrated by admixing comprehensive library of biotinylated PD-Ll-binding peptides (Figure 18). The best-in-class BMS compound showed high tumor accumulation and the highest tumor-to-heart ratio in the in vivo panning, whereas compound 9642 exhibited low tumor-to-heart ratio in the in vivo panning in accordance to significant retention in the heart observed in mouse PET imaging.

[0301] Many peptides with single digit nM activity in vitro exhibited similar low tumor-to-heart ratio (red ovals in Figure 18). Some peptides exhibited additional retention in spleen and liver. Some compounds emerged as candidates for the follow-up re-examination of the individual peptides (9328, 9016, green ovals in Figure 18).3 - Display Of Molecules on Prospectively DNA-Barcoded Nanostructures

[0302] FIG. 19 shows construction of a DEMDOLON object (DNA Encoded Multivalent Display Of Ligands On a Nanoscale) by prospective barcoding wherein “prospective barcoding starts from introducing DNA inside the nanoscale object followed by covalent or non-covalent attachment of molecules to the surface of the object to create a multivalent display of molecules.

[0303] FIG. 20 shows production of DEMDOLON by retroactive barcoding wherein “retroactive barcoding starts from nanoscale objects that already contain a multivalent display of ligands on their surface and introduces a DNA barcode into or onto such object.

[0304] FIG. 21 shows use of DEMDOLON to select molecules that bind to the cells. The figure demonstrates the 1:1 correspondence between the structure of the glycan on the surface of LNP (Lipid NanoParticles) and DNA inside the LNP. DNA barcodes encode either LNP coated with CD33-binding glycolipid or LNP with PEGylated glycolipid. The interactions of the LNPs with CD33 OE cells are decoded by qPCR. Flow cytometry data is shown as reference. (A) Representation of DNA-barcoded LNP-based DEMDOLON displaying active molecules (top) and inactive molecules (bottom). (B) Detection of binding of LNP-based DEMDOLON that binds to CD33 -overexpressing cell by flow cytometry. (C) Detection of binding of LNP-based DEMDOLON that binds to wild-type - 57 -WSLEGAL\055326\00571\44189453v4cell by flow cytometry. (D) Detection of binding of LNP -based DEMDOLON that binds to CD33-knock-out cells by flow cytometry. (E) Detection of binding of LNP-based DEMDOLON that binds to CD33 -overexpressing cell by qPCR. (F) Detection of binding of LNP-based DEMDOLON that binds to wild-type cell by qPCR. (G) Detection of binding of LNP-based DEMDOLON that binds to CD33 -knock-out cells by qPCR. (H) Chemical structure of active and inactive molecules.• Example 3A - Barcoded LNP

[0305] Barcoded LNPs were produced by incorporation of a 126 bp-long DNA. Barcoded liposome 1 formulation can contain ligand that is decoded by DNA 1 and barcoded liposome 2 can contain ligand on its surface that is decoded by DNA 2. The encapsulated DNAs can contain sequences for (1) general qPCR priming, (2) barcode-specific priming, and (3) next-generation sequencing priming.

[0306] An example of barcoded sequence is 5’ - TTTTGGAGATTTTCAACGTGCCGTTATGGTCGAGTTCGATCATATGAACGGAGGAGCCT AGGCTATCGATCGCTGTCAGAGCGTCATTGCGATCGGCCGAAACTGTCCCTCATAGTTA GCGTAACG - 3’ [SEQ ID NO: 31], The dsDNA can be mixed with an ALC-0316 cationic lipid, AF-647 fluorophore, active ligand (e.g. CD33 glycan ligand) to produce a DNA barcoded LNP.

[0307] Barcoded LNPs are produced by incorporation of a 90-bp long single-strand DNA. Barcoded liposome 1 formulation can contain ligand that is decoded by DNA 1 and barcoded liposome 2 can contain ligand on its surface that is decoded by DNA 2. The encapsulated DNAs can contain sequences for (1) general qPCR priming, (2) barcode-specific priming, (3) capture sequence compatible with 10X genomics single-cell RNA sequencing, and (4) Truseq DNA region. An example of barcoded sequence is 5’ - GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGTACCCATAAATCGTAGCTAGTCCA AGCTGTTGCGCTTTAAGGCCGGTCCTAGCAA- 3’ [SEQ ID NO: 32],• Example 3B - Barcoded Mammalian Cells that Express SpyCatcher

[0308] Two cells can have two different types of ligands that can be clicked on SpyCatcher displayed on the cell surface. Each SpyCatcher-displaying cell is barcoded by the SpyCatcher gene so SpyCatcher barcode 1, for example, can be linked to SpyTag-ligand 1 and SpyCatcher barcode 2 can be linked to SpyTag-ligand 2. The SpyCatcher is barcoded at the N-terminus using degenerated codons - 58 -WSLEGAL\055326\00571\44189453v4that be produced by whole-plasmid PCR. A pDNA5 vector containing the SpyCatcher gene fused to the CD33 membrane domain can be used. To introduce the degenerated sequence, we can PCR the whole plasmid using primers 5’ - GATACCAGGTCACCACNCTNAGRGGNCTNTCNGGNGARCARGGNCCNAGYGGCGATAT GACCACAGAAG- 3’ [SEQ ID NO: 33] and 5’ - TGGTATCGGTGACCATAGCGCCTTGGAAG -3’ [SEQ ID NO: 34], The linearized product can be digested with BstEII restriction enzyme and nondigested parental vector can be removed by digestion with Dpnl enzyme.

[0309] Self-ligation can be performed and the vector can be transformed into E.coli for plasmid propagation. To isolate the barcodes, vectors can be purified from cultures of bacterial colonies and submitted for Sanger sequencing. Clones were can then be transfected into CHO mammalian cells (stable transfection). Hygromycin B can be used to select cells containing the degenerated SpyCatcher gene incorporated into the genome.• Example 3C - Barcoded Virus Transducing Different Codon Spelling of mScarlet into a Cell In vitro or In vivo

[0310] Virus can be used to transduce and barcode cells. Cells that were transduced with the mScarlet gene can be barcoded and identified by fluorescence. The mScarlet gene can be PCRed from DNA template using primers 5’ - GATACCAGCTAGCTTTTGGAGATTTTCAACGTGTTAATTAAATGGAYAGYACNGARGCN GTNATHAARGARTTYATGCGNTTYAARGTGCATATGGAAGGCAG - 3’ [SEQ ID NO: 35] and 5’ GATACCAACCGGTCCCTCATAGTTAGCGTAACGAGCGCTTTAGCTGCCGCCGCTGC - 3’ [SEQ ID NO: 36], The amplified DNA can contain a degenerated N-terminus sequence of the mScarlet gene, NF10 / -96 qPCR priming sites and restriction enzymes adapters (NheUPacI at the 5’ regions and AfeHAgel at the 3’ region) that enables cloning into RP174 plasmid. The library of vectors can be introduced into mammalian cells by transduction cloning method using lentivirus.• Example 3D - Barcoded LNP Transducing Different Codon Spelling of mScarlet into any Cell In vitro or In vivo

[0311] Barcoded LNP can be used to transduce and barcode cells. The mScarlet gene can be PCRed from DNA template using primers 5’ - - 59 -WSLEGAL\055326\00571\44189453v4GATACCAGCTAGCTTTTGGAGATTTTCAACGTGTTAATTAAATGGAYAGYACNGARGCN GTNATHAARGARTTYATGCGNTTYAARGTGCATATGGAAGGCAG - 3’ [SEQ ID NO: 37] and 5’ GATACCAACCGGTCCCTCATAGTTAGCGTAACGAGCGCTTTAGCTGCCGCCGCTGC - 3’ [SEQ ID NO: 38], The amplified DNA cam contain a degenerated N-terminus sequence of the mScarlet gene, NF10 / -96 qPCR priming sites and restriction enzymes adapters (NheUPacI at the 5’ regions and AfeHAgel at the 3 ’ region) that enables cloning into RP 174 plasmid. The library of vectors can be introduced into LNPs by mixing with a cationic lipid ALC-0315 as well as a cell-specific ligands for targeted delivery of the vector into any cell in vitro or in vivo.• Example 3E - Barcoded Virus on any Genus Distinguishable by any DNA Variation in Genome

[0312] Two clones of bacteriophage QP or M13 phage can be isolated post bacterial infection, and any DNA variation present in the genome from each of the clones can be used as a barcode. Each bacteriophage can be submitted to a chemical modification and associated with a particular barcode.• Example 3F - Barcoded Protein Cage containing DNA

[0313] To produce barcoded protein cage nanostructures, purified nucleic acids and positively charged capsomers can be mixed. The protein cage and DNA can be assembled in vitro. These DNA-barcoded phages can then be used as delivery systems for mammalian cells with external modifications of the capsid with a ligand of interest. The protein cage can be modified with chemical 1 to produce barcoded protein cage 1 and modify protein cage with chemical 2 to produce barcoded protein cage 2.• Example 3G - Barcoded Plastic Spheres containing DNA

[0314] In this example, plastic spheres are used as non-biological carriers for a DNA-encoded display library. Each plastic sphere population contains, carries, or is otherwise associated with a distinct DNA barcode and is functionalized to display one or more ligands, biomolecules, adapters, or reactive handles on an accessible surface. FIG. 22 shows use of DEMDOLON to select molecules that bind to a protein.

[0315] FIG. 23 shows the anticipated use of DEMDOLON to select molecules that improve delivery and transduction of encapsulated nucleic acids or their derivatives to a specific cell type. In this case it is convenient if barcodes in DEMDOLON are sequences of DNA that encode a reporter - 60 -WSLEGAL\055326\00571\44189453v4protein. A reporter protein can be any protein which is detectable, such as those whose expression can be detected by visual signal (GFP, Luciferase, galactosidase), affinity pulldown (FLAG peptide on the cell surface protein, SpyCatcher receptors), or function (antibiotic resistance). FIG. 24 shows an example of DEMDOLON made by “ prospective barcoding" by transfection of two DNA barcodes inside two cells that have two different molecules on their surface. A) production by retroactive barcoding by transfection of DNA barcode using liposome-based transfection reagent to barcode cell type 1 and cell type 2 (e.g. cell type 1 corresponds to WT CHO cells and it has a lot of terminal sialic acid on glycans in the glycocalyx and low terminal galactose, whereas cell type 2 corresponds to WT CHO cells treated with neuraminidase H and has no terminal sialic acid and high concentration of terminal galactose). (B) Cell mixture containing prospectively barcoded cells. Each cell type has a unique DNA barcode enabling their identification by qPCR or next-generation sequencing upon binding to a target. (C) selection of cell-based DEMDOLON that binds to a specific protein (e.g. target proteins are lectins (1) SNA that binds to sialic acid and (2) PNA that binds to terminal galactose). (D) Detection of binding of cell-based DEMDOLON that binds to PNA protein displayed on beads by qPCR. (E) Representative glycan structures displayed by WT and WT CHO cells treated with neuraminidase H.

[0316] FIG. 25 shows example of DEMDOLON made by “retroactive barcoding by transfection of two DNA barcodes inside two cells that have two different molecules on their surface. A) production by retroactive barcoding by transfection of DNA barcode using liposome-based transfection reagent to barcode cell type 1 and cell type 2 (e.g. cell type 1 corresponds to WT CHO cells and it has a lot of terminal sialic acid on glycans in the glycocalyx and low terminal galactose, whereas cell type 2 corresponds to CMASKOCHO cells and has no terminal sialic acid and high concentration of terminal galactose). (B) Cell mixture containing prospectively barcoded cells. Each cell type has a unique DNA barcode enabling their identification by qPCR or next-generation sequencing upon binding to a target. C) selection of cell-based DEMDOLON that binds to a specific protein (e.g. target proteins are lectins (1) SNA that binds to sialic acid and (2) PNA that binds to terminal galactose). D) Detection of binding of cell-based DEMDOLON that binds to PNA protein displayed on beads by qPCR. E) Representative glycan structures displayed by WT and CMASKOCHO cells.- 61 -WSLEGAL\055326\00571\44189453v4

[0317] FIG. 26 shows anticipated outcome from DEMDOLON screen that identifies a molecular composition that improves delivery of nucleic acid to one cell type. (A) A composition of four DEMDOLON (high mannose, transferrin receptor binder, tri-GalNAc, blank). ( B) The screen uses a mixture of barcoded liposomes (DEMDOLON) and three or more different cell types (for example, hepatocytes, B-cells and red blood cell). Cells that have taken up the DNA become fluorescent and can be sorted from cells that do not contain any barcode. The barcodes are identifiable by NGS for each desirable cell type. (C) Anticipated results observed by sequencing the DNA inside transduced cell types. (D) The same screen can be used in animal models (e.g. wild type mouse). A mixture of DNA barcoded liposome is injected into mice. Animal organs are harvested, and the cells are isolated and sorted for identification of the DNA barcodes associated with each desirable cell type.IV. INTERPRETATION

[0318] Various systems or methods have been described to provide an example of an embodiment of the claimed subject matter. No embodiment described limits any claimed subject matter and any claimed subject matter may cover methods or systems that differ from those described below. The claimed subject matter is not limited to systems or methods having all of the features of any one system or method described below or to features common to multiple or all of the apparatuses or methods described below. It is possible that a system or method described is not an embodiment that is recited in any claimed subject matter. Any subject matter disclosed in a system or method described that is not claimed in this document may be the subject matter of another protective instrument, for example, a continuing patent application, and the applicants, inventors or owners do not intend to abandon, disclaim or dedicate to the public any such subject matter by its disclosure in this document.

[0319] Furthermore, it will be appreciated that for simplicity and clarity of illustration, where considered appropriate, reference numerals may be repeated among the figures to indicate corresponding or analogous elements. In addition, numerous specific details are set forth in order to provide a thorough understanding of the embodiments described herein. However, it will be understood by those of ordinary skill in the art that the embodiments described herein may be practiced without these specific details. In other instances, well-known methods, procedures and components- 62 -WSLEGAL\055326\00571\44189453v4have not been described in detail so as not to obscure the embodiments described herein. Also, the description is not to be considered as limiting the scope of the embodiments described herein.

[0320] It should also be noted that the terms “coupled” or “coupling” as used herein can have several different meanings depending in the context in which these terms are used. For example, the terms coupled or coupling may be used to indicate that an element or device can electrically, optically, or wirelessly send data to another element or device as well as receive data from another element or device. As used herein, two or more components are said to be “coupled”, or “connected” where the parts are joined or operate together either directly or indirectly (i.e., through one or more intermediate components), so long as a link occurs. As used herein and in the claims, two or more parts are said to be “directly coupled”, or “directly connected”, where the parts are joined or operate together without intervening intermediate components.

[0321] It should be noted that terms of degree such as "substantially", "about" and "approximately" as used herein mean a reasonable amount of deviation of the modified term such that the end result is not significantly changed. These terms of degree may also be construed as including a deviation of the modified term if this deviation would not negate the meaning of the term it modifies.

[0322] Furthermore, any recitation of numerical ranges by endpoints herein includes all numbers and fractions subsumed within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.90, 4, and 5). It is also to be understood that all numbers and fractions thereof are presumed to be modified by the term "about" which means a variation of up to a certain amount of the number to which reference is being made if the end result is not significantly changed.

[0323] The present invention has been described here by way of example only, while numerous specific details are set forth herein in order to provide a thorough understanding of the exemplary embodiments described herein. However, it will be understood by those of ordinary skill in the art that these embodiments may, in some cases, be practiced without these specific details. In other instances, well-known methods, procedures and components have not been described in detail so as not to obscure the description of the embodiments. Various modification and variations may be made to these exemplary embodiments without departing from the spirit and scope of the invention, which is limited only by the appended claims.- 63 -WSLEGAL\055326\00571\44189453v4VII. REFERENCES

[0324] All publications, patents and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains and, if permitted, are herein incorporated by reference to the same extent as if each individual publication, patent, or patent applications was specifically and individually indicated to be incorporated by reference.1. Laskowski, R. A.; Gerick, F.; Thornton, J. M., The structural basis of allosteric regulation in proteins. FEBS leters 2009, 583 (11), 1692-1698.2. Shivatare, S. S.; Chang, S.-H.; Tsai, T.-I.; Tseng, S. Y.; Shivatare, V. S.; Lin, Y.-S.; Cheng, Y - Y.; Ren, C.-T.; Lee, C.-C. D.; Pawar, S., Modular synthesis ofN-glycans and arrays for the heteroligand binding analysis of HIV antibodies. Nature Chemistry 2016, 8 (4), 338- 346.3. Johnson, Q. R.; Lindsay, R. J.; Petridis, L.; Shen, T., Investigation of carbohydrate recognition via computer simulation. Molecules 2015, 20 (5), 7700-7718.4. Watanabe, M.; Nakamura, O.; Muramoto, K.; Ogawa, T., Allosteric regulation of the carbohydrate-binding ability of a novel conger eel galectin by D-mannoside. Journal of Biological Chemistry 2012, 287 (37), 31061-31072.5. Kelly, H. G.; Kent, S. J.; Wheatley, A. K., Immunological basis for enhanced immunity of nanoparticle vaccines. Expert Review of Vaccines 2019, 18 (3), 269-280.6. Ols, S.; Lenart, K.; Cerveira, R. A.; Miranda, M. C.; Brunette, N.; Kochmann, J.; Corcoran, M.; Skotheim, R.; Philomin, A.; Cagigi, A., Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses. Immunity 2023, 56 (10), 2425-2441. el4.7. Sojitra, M.; Sarkar, S.; Maghera, J.; Rodrigues, E.; Carpenter, E. J.; Seth, S.;Ferrer Vinals, D.;Bennett, N. J.; Reddy, R.; Khalil, A., Genetically encoded multivalent liquid glycan array displayed on Ml 3 bacteriophage. Nature chemical biology 2021, 17 (7), 806-816.8. Lima, G. M.; Chenarboo, Z. J.; Sojitra, M.; Sarkar, S.; Carpenter, E. J.; Yang, C. Y.-L.;Schmidt, E.; Lai, J.; Atrazhev, A.; Yazdan, D., Multivalent DNA-encoded lectins on phage enable detecting compositional glycocalyx differences. bioRxiv 2023, 2023.12. 13.571601.9. Scott, J. K.; Smith, G. P., Searching for peptide ligands with an epitope library. Science 1990,249 (4967), 386-390.10. Rakonjac, J.; Bennett, N. J.; Spagnuolo, J.; Gagic, D.; Russel, M., Filamentous bacteriophage:biology, phage display and nanotechnology applications. Current issues in molecular biology 2011, 73 (2), 51-76.11. Tjhung, K. F.; Kitov, P. I.; Ng, S.; Kitova, E. N.; Deng, L.; Klassen, J. S.; Derda, R., Silent encoding of chemical post-translational modifications in phage-displayed libraries. Journal of - 64 -WSLEGAL\055326\00571\44189453v4the American Chemical Society 2016, 138 (1), 32-35.12. Tuerk, C.; Gold, L., Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase, science 1990, 249 (4968), 505-510.13. Ellington, A. D.; Szostak, J. W ., In vitro selection of RNA molecules that bind specific ligands.nature 1990, 346 (6287), 818-822.14. McKinnon, K. M., Flow cytometry: an overview. Current protocols in immunology 2018, 120 (1), 5.1. 1-5.1. 11.15. Robinson, J. P.; Ostafe, R.; Iyengar, S. N.; Rajwa, B.; Fischer, R., Flow cytometry: the next revolution. Cells 2023, 72 (14), 1875.16. Simoni, Y.; Chng, M. H. Y.; Li, S.; Fehlings, M.; Newell, E. W ., Mass cytometry: a powerful tool for dissecting the immune landscape. Current opinion in immunology 2018, 57, 187-196.17. Stoeckius, M.; Hafemeister, C.; Stephenson, W.; Houck-Loomis, B.; Chattopadhyay, 18. P. K.; Swerdlow, H.; Satija, R.; Smibert, P., Simultaneous epitope and transcriptome measurement in single cells. Nature methods 2017, 14 (9), 865-868.19. Fiskin, E.; Lareau, C. A.; Ludwig, L. S.; Eraslan, G.; Liu, F.; Ring, A. M.; Xavier, R. J.; Regev, A., Single-cell profiling of proteins and chromatin accessibility using PHAGE- AT AC. Nature biotechnology 2022, 40 (3), 374-381.20. Pollock, S. B.; Hu, A.; Mou, Y.; Martinko, A. J.; Julien, O.; Hornsby, M.; Ploder, L.; Adams, J. J.; Geng, H.; Miischen, M., Highly multiplexed and quantitative cell-surface protein profiling using genetically barcoded antibodies. Proceedings of the National Academy of Sciences 2018, 775 (11), 2836-2841.21. Kiessling, L. L.; Gestwicki, J. E.; Strong, L. E., Synthetic multivalent ligands as probes of signal transduction. Angewandte Chemie International Edition 2006, 45(15), 2348-2368.22. Jung, J.; Enterina, J. R.; Bui, D. T.; Mozaneh, F.; Lin, P.-H.; Nitin; Kuo, C.-W.; Rodrigues, E.;Bhattacherjee, A.; Raeisimakiani, P., Carbohydrate sulfation as a mechanism for fine-tuning Siglec ligands. ACS Chemical Biology 2021, 16 (11), 2673-2689.23. Lima, G. M.; Jame-Chenarboo, Z.; Sojitra, M.; Sarkar, S.; Carpenter, E. J.; Yang, C. Y.;Schmidt, E.; Lai, J.; Atrazhev, A.; Yazdan, D. The liquid lectin array detects compositional glycocalyx differences using multivalent DNA-encoded lectins on phage. Cell Chemical Biology 2024.- 65 -WSLEGAL\055326\00571\44189453v4

Claims

CLAIMS:

1. A multivalent display library, comprising at least one nanocarrier population comprising nanocarriers associated with at least one distinct barcode, wherein the nanocarriers bear a surface universal adapter and a ligand associated with the universal adapter, wherein the barcode uniquely encodes the identity of the ligand and / or a ligand property such as ligand density, and wherein the universal adapter is non-covalently attached to the ligand.

2. The library of claim 1, wherein the at least one distinct barcode is a silent barcode.

3. The library of claim 2, comprising two or more different nanocarrier populations, wherein each population comprises a different silent barcode, and each population differs in the identity of the ligand or a ligand property.

4. The library of claim 3 wherein ligand property is a display density of the ligand on the nanocarrier.

5. The library of any one of claims 1-4, wherein the barcode is prospectively associated with the nanocarriers, or is retrospectively associated with the nanocarriers.

6. The library of any one of claims 1-5, wherein the universal adapter is streptavidin, avidin, neutravidin, a streptavidin-derived protein, dihydrofolate reductase, an antibody, or a protein that binds a small organic molecule or peptide with a dissociation constant of 10 nM or lower.

7. The library of claim 6, wherein the universal adapter is streptavidin and the ligand is biotinylated.

8. The library of any one of claims 1-7, wherein the nanocarriers comprises cells, viruses such as phages such as bacteriophages, virus-like particles, liposomes, lipid nanoparticles, exosomes, vesicles, polymeric particles, nanoparticles, synthetic particles, or combinations thereof.

9. The library of claim 8 wherein the nanocarrier comprises a phage, such as bacteriophage, such as M13.- 66 -WSLEGAL\055326\00571\44189453v410. The library of any one of claims 1-9 wherein the ligand is a glycan-binding protein, such as a lectin.

11. A method of characterizing a target, comprising contacting the target with a library of any one of claims 1-10, and analyzing the binding of the at least one nanocarrier population to the target.

12. The method of claim 11, wherein the target is a heterogenous target, and the library is a mixed library of claim 3 or any claim dependent on claim 3, and analyzing the binding of the different nanocarrier populations to the heterogenous target.

13. The method of claim 12, wherein the different nanocarrier populations each comprise a different lectin and / or a different display density of a lectin, and the heterogenous target is a glycocalyx.

14. A method of preparing a multivalent display library comprising at least one nanocarrier population, comprising the steps of:a. attaching a universal adapter to each nanocarrier and non-covalently associating a ligand with the universal adapter, such that the nanocarrier displays the ligand; andb. associating at least one distinct barcode with the at least one nanocarrier population, such that the barcode uniquely identifies the ligand and / or a ligand property.

15. The method of claim 14, comprising the step of combining at least two different nanocarrier populations, wherein each population comprises a different silent barcode, and each population differs in the identity of the ligand or a ligand property.- 67 -WSLEGAL\055326\00571\44189453v4